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1 Summary
MyoD is one of the MRFs (Muscle Regulatory Factors) and it functions to determine the
muscle cell fate. The mechanism by which MyoD regulates the muscle development
program is very well understood. However, the transcriptional regulation of the MyoD
gene itself has not studied in Xenopus. In this thesis, I have analyzed the transcriptional
regulatory mechanism of the MyoD gene in Xenopus by different approaches, which
include transgenic reporter analysis of its cis-regulatory elements of MyoD transcription
and gain-of-function and loss-of-function tests of several potential regulaters.
Here I showed that the expression of the XmyoD gene is controlled by a combination of
induction, repression and maintenance. One activating motif, one repressing motif and
one maintenance motif were found by transgenic reporter analysis. XSRF (Xenopus
serum response factor) binds with the maintenance enhancer to maintain the expression
of XmyoD gene. A repetitive DNA sequence was discovered in the -2.8/-2.0kb region in
the XmyoD genomic sequence. The repetitive DNA sequence in the XmyoD gene locus
may produce sense and anti-sense transcripts. In addition, several potential regulators
have been analyzed. It has been shown that XSEB-4, a direct target of XmyoD protein, is
able to induce the expression of XmyoD gene. Xenopus Ying Yang 1 (XYY1) can repress
the expression of the XmyoD gene. Lef-1 is necessary and sufficient for the expression of
XmyoD gene. This provides strong evidence that Lef-1 is the transcription factor of the
zygotic Wnt signaling pathway that activates the expression of the XmyoD gene.
2. Introduction
2
2 Introduction
2.1 Early development and mesoderm patterning of Xenopus
With its rapid embryonic development, large egg size (1–2 mm in diameter) and high
numbers of embryos (1,500 per female), Xenopus provides a favorable model system for
the study of vertebrate development, and it has been used extensively to analyse the
events in early embryogenesis (Figure 2.1).
2.1.1 Frog embryology
The frog egg is radially symmetrical and is divided into an animal and a vegetal domain.
During embryonic development, the egg is converted into a tadpole containing millions
of cells but containing the same volume of material.
Entrance of the sperm initiates a sequence of events: The cytoplasm of the egg rotates
about 30 degrees relative to the point of sperm entry. It foretells the future pattern of the
animal: its dorsal (D) and ventral (V) surfaces, its anterior (A) and posterior (P), its left
and right sides. The haploid sperm and egg nuclei fuse to form the diploid zygote
nucleus.
The fertilized egg undergoes a series of mitoses. The first cleavage occurs shortly after
the zygotic nucleus forms. A furrow appears that runs longitudinally through the poles of
the egg, passing through the point at which the sperm entered. This divides the egg into
two halves forming the 2-cell stage. The second cleavage forms the 4-cell stage. The
cleavage furrow again runs through the poles but at right angles to the first furrow.
The furrow in the third cleavage runs horizontally but in a plane closer to the animal than
to the vegetal pole. It produces the 8-cell stage. The next few cleavages also proceed in
synchrony, producing a 16-cell and then a 32-cell embryo. However, as cleavage
continues, the cells in the animal pole begin dividing more rapidly than those in the
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vegetal pole and thus become smaller and more numerous after midblastula transition
(MBT).
Figure 2.1 The anatomy of Xenopus development. 
The ovarian oocyte is radially symmetrical and is divided into an animal and a vegetal domain.
One hour after fertilization, an unpigmented dorsal crescent is formed in the fertilized egg
opposite the sperm entry point. As the embryo rapidly divides into smaller and smaller cells,
without intervening growth, a cavity called the blastocoel is formed, which defines the blastula
stage. By the late blastula stage (9 h of development), the three germ layers become defined. The
ectoderm, or animal cap, forms the roof of the blastocoel. The mesoderm is formed in a ring of
cells in the marginal zone, located between the ectoderm and endoderm. At the gastrula stage
(10 h), involution of the mesoderm towards the inside of the embryo starts at the dorsal
blastopore lip. The morphogenetic movements of gastrulation lead to the formation of the
vertebrate body plan, patterning the ectoderm, mesoderm and endoderm. At the neurula stage
(14 h), the neural plate, or future central nervous system (CNS), becomes visible in dorsal
ectoderm. By the tailbud stage (24–42 h), a larva with a neural tube located between the
epidermis and the notochord has formed. The blastopore gives rise to the anus, and the mouth is
generated by secondary perforation. (Adapted from De Robertis et al., 2000)
2. Introduction
4
Several hours later, continued cleavage has produced a hollow ball of thousands of cells
called the blastula. A fluid-filled cavity, the blastocoel, forms within it. During this entire
process there has been no growth of the embryo. There has been no transcription and
translation of zygote genes. All of the activities up to now have been run by gene
products (mRNA and proteins) deposited by the mother when she formed the egg. After
MBT, the zygotic genes start to be transcripted and translated.
The start of gastrulation is marked by the invagination of cells in the region of the
embryo that was once occupied by the middle of the dorsal crescent. This produces both
an opening (the blastopore) that will be the future anus and a cluster of cells that develops
into the Spemann organizer.
As gastrulation continues, three distinct germ layers are formed: ectoderm, mesoderm,
endoderm. Each of which will have special roles to play in building the complete animal.
Some of these are listed in the table. Muscle is derived from mesoderm.
Ectoderm Mesoderm Endoderm
skin notochord lining of gut
brain muscles lining of lungs
spinal cord blood lining of bladder
all other neurons bone liver
sense receptors sex organs pancreas
2.1.2 Mesoderm induction
After the midblastula stage, endoderm releases mesoderm-inducing signals (Wylie et al.,
1996; for review see De Robertis, et al., 2000), which has been investigated
experimentally by combining explants of vegetal and animal tissue. The established view
from embryological studies was that the endoderm releases two signals, one from the
ventral endoderm, which induces ventral mesoderm, and a second from the dorsal
endoderm (Nieuwkoop center), which induces dorsal mesoderm (Spemann's organizer).
A third signal subsequently emanates from the Spemann's organizer to refine the initial
dorsal–ventral pattern (Heasman, 1997) (Figure 2.2).
2. Introduction
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Figure 2.2 Two-step model of mesoderm induction in Xenopus.
At the midblastula stage, higher ß-Catenin levels on the dorsal side of the embryo, together with
the vegetally located transcription factor VegT and the maternal TGF-ß family growth factor
Vg1, generate a gradient of Nodal-related molecules expressed in the endoderm. In turn, this
gradient induces the formation of overlying mesoderm: low doses of Nodal-related molecules
(Xnrs) lead to the formation of ventral mesoderm, whereas high doses lead to the establishment
of Spemann's organizer. Nieuwkoop's centre is the region of dorsal endoderm that induces
organizer tissue. At the gastrula stage, the organizer secretes a cocktail of factors that refine the
initial patterning. Note that ß-Catenin is widely distributed on the dorsal side, including in
derivatives of the three germ layers. (CNS, central nervous system.) (Adapted from De Robertis
et al., 2000)
Nodal-related proteins (Xnrs), which belong to the transforming growth factor (TGF)-β
family of growth factors, have important functions in mesoderm formation in different
species. At the blastula stage, Xnrs are expressed in a dorsal to ventral gradient in
endodermal cells (Agius et al., 2000), which is accompanied by the preferential
phosphorylation of Smad2 (a downstream effector of TGF-β signaling) on the dorsal side
(Faure et al., 2000). Nodal-related proteins function as a morphogen — molecules that
directly determine cell fates within a field of cells in concentration-dependent manner —
to induce ventral and posterior mesodermal markers at lower doses and progressively
more dorsal and anterior markers at higher dosage (Green et al., 1992; Jones et al., 1995;
Agius et al., 2000).
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The gradient of Xnr expression in the endoderm is thought to be activated by three
maternally provided molecules: Vg1, VegT and ß-catenin (Figure 2.2). Vg1, a TGF-β
factor, and VegT, a T-box transcription factor, are both localized to the vegetal pole of
the Xenopus oocyte and are potent inducers of endoderm (Henry & Melton, 1998; Zhang
et al., 1998). Depletion of maternal VegT leads to the absence of endoderm. In VegT-
depleted embryos, Xnr transcription and mesoderm formation are severely inhibited and
can be rescued by injection of Xnr mRNA (Kofron et al., 1999). Wild-type embryos
microinjected with VegT and Vg1 have only low levels of Xnr transcription; however,
when ß-catenin is also provided, it cooperates with VegT and Vg1 to achieve the high
levels of Xnr expression that cause organizer induction (Agius et al., 2000) (Figure 2.2).
In conclusion, after the midblastula satge, the ß-catenin signal, in combination with other
maternal genes, activates a dorsal–ventral gradient of several Nodal-related signals in the
endoderm that, in turn, mediate the induction and patterning of the mesodermal layer.
2.2 Muscle development
Skeletal muscle derives from the mesoderm and it has been a paradigm for cell
specification and cell differentiation (for review see Perry and Rudnicki, 2000; Pownall
et al., 2002). The original cloning of MyoD and its characterization as a master regulatory
gene for the determination of skeletal muscle, started a new era of research in skeletal
myogenesis. This discovery led to the cloning of three other muscle regulatory factors
(MRF) namely Myf5, myogenin, and MRF4. In all cases, overexpresison of these factors
converts non-muscle cells to the myogenic lineage, demonstrating their role in myogenic
lineage determination and differentiation. Furthermore, the ability of each factor to
initiate the expression of one or more of the other three suggests they form a cross-
regulatory loop.
The MRFs belong to the basic helix-loop-helix (bHLH) superfamily of transcription
factors. The HLH domain is responsible for the dimerization of these factors with the
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ubiquitously expressed E-proteins, such as E12, E47, HEB, and ITF, and the basic
domain is responsible for DNA binding. Heterodimers bind to the consensus E-box (5’-
CANNTG-3’) DNA sequence motif found in the promoters of many muscle specific
genes. The bHLH domains of the MRFs are highly homologous while the amino and
carboxyl terminal ends show limited homology. Structurally, the MRFs contain several
functionally distinct domains responsible for transcriptional activation, chromatin
remodeling, DNA binding, nuclear localization and heterodimerization (for review see
Rupp et al., 2002).
2.3 MRF expression in vertebrate embryos
2.3.1 MRF expression in muscle progenitors of the mouse embryo
During mouse development, the MRFs are expressed in a highly regulated spatial and
temporal fashion (reviewed in Arnold & Braun, 2000). Gene expression studies using in
situ hybridization techniques showed that MRF expression occurs in slightly different
patterns in epaxial versus hypaxial muscle. Myf5 is expressed in the dorsomedial portion
of the somite at 8 days post coitus (p.c.) and at day 9.5 in the lateral, or hypaxial domain
of the somite (Ott et al., 1991). The expression of Myogenin is first detected at day 8.5
p.c. and remains detectable throughout fetal development (Sassoon et al., 1989). The
expression of MRF4 is detected transiently between days 10 and 11 and then reexpressed
from day 16 onward to become the predominant MRF expressed in adult muscle (Bober
et al., 1991; Hinterberger et al., 1991; Hannon et al., 1992). MyoD expression is first
detected approximately at day 9.75 in the hypaxial somitic domain and continues to be
expressed throughout development (Bober et al., 1991; Faerman et al., 1995). In the limb
bud, the temporal expression of these factors is slightly different. Although Myf5
expression is again detected first, it is followed very quickly by MyoD and myogenin
which are detected from day 10.5 onward (Ott et al., 1991; Sassoon et al., 1989). Unlike
observations in the somite, MRF4 is not transiently expressed during limb development,
but is first detected at day 16 and becomes the predominant MRF expressed in the adult
(Bober et al., 1991, Hinterberger et al., 1991).
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2.3.2 MRF expression in muscle progenitors of the frog embryo
Xenopus development is very rapid from fertilized egg to swimming tadpole, which
requirs the production of large myotomal swimming muscles. Xenopus embryo fate maps
have been constructed (Bauer et al., 1994; Dale and Slack, 1987; Keller, 1976), and
mesodermal cells have been identified to give rise to the somites that form these
myotomal muscles.
Figure 2.3 XmyoD and Xmyf5 are expressed in myogenic precursors of Xenopus laevis embryos.
(A) There is no XmyoD expression at Nieuwkoop and Farber (NF) stage 10. (B) Xmyf5 expresses
in organizer region at NF 10. (C, D) NF stage 11 gastrula embryos, viewed from the vegetal
hemisphere. XmyoD (C) is expressed in a broad domain but is restricted from the dorsal
organizer region, whereas Xmyf5 (D) is expressed mainly dorsally at this stage. (E, F) NF stage
16 neurula embryos viewed dorsally. XmyoD (E) is expressed in myogenic precursors along the
entire anteroposterior axis, whereas Xmyf5 (F) expression is restricted to a more posterior
domain. (G, H) Tailbud stage embryos viewed laterally with anterior to the left. XmyoD (G) is
expressed in the somite myotome and in myogenic progenitors in the head. Xmyf5 (H)
expression is high in the posterior unsegmented mesoderm and becomes restricted to the dorsal
and ventral somite. (A, C, E, G, Xiao and Rupp, unpublished data; B, D, F, H, adapted from
Yang et al., 2002)
XmyoD is transiently expressed in all cells at the mid-blastula transition (Rupp &
Weintraub, 1991). During early gastrulation, XmyoD RNA is upregulated specifically in
mesodermal progenitors (Figure 2.3 C). XmyoD protein is detected by mid-gastrulation
and after 2h, expression of cardiac-actin is activated, which is an early muscle
differentiation gene (Hopwood et al., 1989, 1992). Xmyf5 is also activated during early
gastrula stages, and its domain of expression initially extends more dorsally, including
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transient expression in Spemann organizer (Figure 2.3B). During later gastrula stages, the
expression of Xmyf5 is restricted to the dorsolateral mesoderm (Figure 2.3D) (Hopwood
et al., 1991). It has been shown by cell transplantation studies that cells from myogenic
regions of late gastrula embryos, when placed at ectopic ventral sites, can differentiate
into muscle cell autonomously (Kato & Gurdon, 1993). Thus mesodermal cells
expressing XmyoD and Xmyf5 prior to somite formation are specified and comitted for
myogenesis at late gastrula stages. At earlier stages, XmyoD- and Xmyf5-expressing
precursors cannot differentiate ectopically after cell transplantation and therefore require
additional signals to maintain their myogenic potential.
2.4 Functional and genetic relationships of the MRFs
The expression of muscle lineage-specificity of MRF genes in vertebrate embryos
provide evidence that MRFs are regulators in the specification and differentiation of
myogenic progenitor lineages. A framework was established by these findings for genetic
and experimental embryological studies of MRF functions in embryos.
2.4.1 Myogenic functions of MRFs
Myf5 and MyoD were identified as dominant regulators of myogenic progenitor
specification in tissue culture studies that demonstrated their expression in myoblast
progenitors, their myogenic conversion activities in DNA transfection assays, and their
autoregulatory functions. However, when expressed ectopically in embryos, MyoD and
Myf5 have incomplete myogenic functions. Ectopic expression of XmyoD or Xmyf5 in
Xenopus animal pole activates chromosomal XmyoD and cardiac-actin, an early muscle
differentiation gene, but muscle differentiation and the expression of the entire array of
muscle protein genes are not initiated (Hopwood & Gurdon, 1990; Hopwood et al.,
1991), even when these factors are co-expressed with their E12 bHLH partner protein
(Rashbass et al., 1992). In transgenic mouse embryos, ectopic expression of MyoD in
mesoderm and ectoderm lineages (Faerman et al., 1993) or heart (Miner et al., 1992) also
led to autoregulation of chromosomal MyoD and activation of some contractile proteins
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but did not initiate a complete conversion of these lineages into differentiated muscle.
Thus at ectopic sites in the embryo, expression of Myf5 and MyoD can initiate some gene
regulatory processes of myogenic specification, including autoregulation and expression
of early muscle differentiation markers, but not the later regulatory program for muscle
differentiation.
2.4.2 Genetic analysis of Myf5 and MyoD functions in progenitor specification
Targeted inactivation of the MRFs has provided a great deal of insight into the nature of
lineage determination, lineage maintenance and their genetic relationships. MyoD (-/-)
and Myf5 (-/-) mutant mice are viable and fertile (Kaul et al., 2000; Rudnicki et al.,
1992); however, MyoD (-/-); Myf5 (-/-) embryos do not form skeletal muscles and die at
birth because of respiratory failure (Rudnicki et al., 1993). Thus, compensatory
mechanisms allow MyoD and Myf5 to be functionally redundant for skeletal myogenesis,
consistent with the closely related structural homology of these bHLH transcription
factors and their independent regulation for expression at all sites of skeletal myogenesis
in the embryo. This demonstrates that at least one of these factors is required for
determining the myogenic lineage during embryonic development.
2.4.3 Myogenin and MRF4 are regulators of muscle differentiation
In contrast to Myf5 and MyoD, Myogenin and MRF4 have differentiation functions.
Myogenin (-/-) and MRF4 (-/-) mouse embryos form Myf5- and MyoD-expressing muscle
progenitors, but are deficient in differentiated muscles (Nabeshima et al., 1993; Olson et
al., 1996; Venuti et al., 1995). Muscle deficiencies are more severe in Myogenin (-/-)
embryos than in MRF4 (-/-) embryos. The specific muscle differentiation requirements
for MRF4 are not yet well defined.
Together, these gene targeting experiments have suggested a model (Figure 2.4), in
which MyoD and Myf5 act to determine the myoblast lineage, whereas myogenin and
MRF4 are important for differentiation and maintenance of the terminally differentiated
state in mice (Rudnicki & Jaenisch, 1995).
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Figure 2.4 Functional and genetic relationships of the MRFs. Gene targeting experiments
indicate that Myf5 and MyoD are required for the determination of the myogenic lineage.
By contrast, terminal differentiation is dependent upon myogenin and MRF4. (Adapted
from Perry and Rudnicki, 2000)
2.5 Myogenic competence
In Xenopus, cells from the animal hemisphere are competent to form mesodermal tissues
from the morula through to the midgastrula stage (Jones and Woodland, 1987). Loss of
mesodermal competence at early gastrula is programmed cell-autonomously, and occurs
even in single cells at the appropriate stage (Grainger and Gurdon, 1989). Xenopus MyoD
is expressed at low levels at the late blastula stage. Subsequently, MyoD and Myf5
expression are induced by secreted growth factors of the TGF-, Wnt- and FGF-families
(Steinbach et al., 1998) in prospective muscle, when mesoderm forms at the onset of
gastrulation. The timing of MyoD induction in Xenopus embryonic explant assays is
largely independent from the timepoint of inducer application (Steinbach et al., 1998). An
independent mechanism ensures that MyoD transcription can only be induced until the
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midgastrula stage, although signalling pathways, for example that of activin, remain
functional (Steinbach et al., 1997). The loss of MyoD-inducibility coincides precisely
with the disappearance of both muscle-forming competence and general mesodermal
competence. Together, these observations describe a window of opportunity to induce
MyoD transcription of less than two hours, which might reflect the epigenetic state of the
MyoD locus. Indeed, the ability to induce MyoD is under the control of linker histone
proteins, which act as transcriptional inhibitors of MyoD induction (Steinbach et al.,
1997).
2.6 Molecular regulatory mechanisms of Myf5 and MyoD
2.6.1 Modular regulation of Myf5 and MyoD by transcription enhancer cassettes
Transcription enhancers for Myf5 and MyoD in the mouse have been identified by
transgenic analysis using LacZ reporter genes. Studies of the activities of these enhancers
in muscle progenitor lineages in wild-type and mutant embryos have provided insights
into regulatory mechanisms for progenitor cell specification and differentiation and have
defined a direct, molecular approach to complement functional screens to identify
upstream developmental regulators of myogenic specification.
2.6.1.1 Transcription enhancers for MyoD expression in muscle progenitors and
differentiating muscle in mammals
Two MyoD transcription enhancers have been characterized, which are named the core
enhancer (CE) and distal regulatory region (DRR). They are located in the 5' upstream
regions of the human and mouse MyoD genes (Asakura et al., 1995; Goldhamer et al.,
1995; Goldhamer et al., 1992; Tapscott et al., 1992). Each of these enhancers has a
distinct regulatory function. The core enhancer controls MyoD activation in muscle
progenitors (Goldhamer et al., 1995), and the DRR controls MyoD expression in
differentiating muscles (Asakura et al., 1995; J. C. Chen et al., 2001).
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Linker-scanner mutagenesis of this 258-bp sequence has identified multiple cis elements
required for its activity, including an enhancer region specifically required in myotomal
lineages that may represent a target for Myf-5-dependent regulation of M y o D
(Kucharczuk et al., 1999). However, the core enhancer is not sufficient to maintain MyoD
expression in differentiated skeletal muscle, being down-regulated in fetal and neonatal
muscle and essentially inactive in adult muscle. Five kilobases upstream of MyoD is a
second enhancer, the distal regulatory region (DRR), which is unrelated in sequence to
the core enhancer and exhibits largely complementary activity in transgenic mice
(Tapscott et al., 1992; Goldhamer et al., 1995; Asakura et al., 1995; J. C. Chen et al.,
2001). DRR activity is restricted to differentiated skeletal muscle in vivo (Kablar et al.,
1997), which is reflected as a significant delay in DRR-driven transgene expression in
several sites of myogenesis relative to the endogenous MyoD gene (Asakura et al., 1995).
Unlike the core enhancer, the DRR remains active in adult muscle, showing a similar
expression profile as the endogenous MyoD gene (Chen et al., 2002). Collectively, these
data indicate that the core enhancer and DRR have distinct activation and maintenance
functions, respectively, that collaborate to establish the dynamic pattern of MyoD
expression in embryonic and adult skeletal muscle (J. C. Chen et al., 2001).
2.6.1.2 Lineage-specific Myf5 transcription enhancers
Multiple transcription enhancers control Myf5 expression, which have been identified by
systematic transgenic analysis of a 500-kb sequence region around the mouse MRF4-
Myf5 locus (Carvajal et al., 2001; Hadchouel et al., 2000; Patapoutian et al., 1993;
Summerbell et al., 2000; Zweigerdt et al., 1997). These enhancers are distributed in a 90-
kb region around the MRF4-Myf5 locus, and different enhancer cassettes control lineage-
specific transcription of Myf5 in epaxial, hypaxial, limb, and head muscle progenitors.
The lineage-specific epaxial, hypaxial, and branchial arch enhancers are located in the
MRF4-Myf5 locus, whereas the limb enhancer and an associated myotome differentiation
enhancer are located 58 kb upstream of the locus, embedded in the intronic sequences of
a nonmuscle gene (Carvajal et al., 2001; Hadchouel et al., 2000). These enhancers likely
regulate the Myf5 promoter and not the closely linked MRF4 promoter, based on their
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temporal activities, which coincide with the transcriptional activity of Myf5 and not
MRF4. MRF4 regulatory elements have been located 5' of the MRF4 promoter (Black et
al., 1995; Naidu et al., 1995; Pin et al., 1997). The close linkage of MRF4 and Myf5 and
their differential expression in progenitors and differentiated muscle cells predicts the
presence of insulator elements (Muller, 2000) to direct specific enhancer activities to the
MRF4 and Myf5 promoters.
Some analyses of the regulatory elements in the frog Myf5 locus have been done (Polli &
Amaya, 2002; Yang et al., 2002a). Polli and Amaya showed that HBX2, an essential
element approximately 1.2 kb upstream from the start of transcription, is necessary for
both activation and repression of Myf-5 expression. Yang et al. (2002a) showed that a
distal TCF-3 binding site is necessary to repress the expression of Myf-5 in non-muscle
forming mesoderm (organizer and ventral marginal zone) during gastrulation.
2.7 Developmental signaling that controls MRF expression
2.7.1 Myogenic signals in mice
Several factors are expressed in axial and lateral regions of the developing embryo which
are important for somite formation and the determination of cell lineages (Figure 2.5; for
review see Perry and Rudnicki, 2000). Axial structures, such as the neural tube and
notochord, provide signals necessary for epaxial myogenic determination. By contrast,
the hypaxial myogenic lineage is dependent upon signals originating from the lateral
plate mesoderm and dorsal ectoderm. Factors secreted from these structures include sonic
hedgehog (Shh), Wnts, transforming growth factor-beta (TGF-beta)-like molecules,
fibroblast growth factors (FGFs) and bone morphogenic proteins (BMPs). All of these
factors regulate myogenic determination and differentiation. However, there are
differential effects observed between epaxial and hypaxial musculature.
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Figure 2.5 Extracellular growth factors which are important for myotomal development. Sonic
hedgehog is secreted by both notochord and floor plate which serves to induce Myf5 expression.
Wnts, in particular Wnt1, secreted from the dorsal neural tube similarly induce Myf5 expression
in the epaxial myotome. By contrast, Wnt7a secreted from the dorsal ectoderm induces MyoD
expression in the ventral myotome. BMP4 secreted from the dorsal ectoderm and lateral plate
mesoderm is important for repressing MRF activation and maintaining Pax3 expression in cells
of the dermomyotome and the migrating precursor population in the VLL. Both dorsal neural
tube and the DML secrete noggin, inhibiting the repressive effects of BMP4 on myogenesis.
DML=dorsomedial lip; VLL=ventrolateral lip; DE=dorsal ectoderm; NT=neural tube;
NC=notochord; MM=medial myotome; VM=ventral myotome. (Adapted from Perry and
Rudnicki, 2000.)
Sonic hedgehog (Shh) is expressed in the notochord and neural floor plate and has been
shown to positively regulate the formation and survival of the dorsal myotome. In
association with Shh, several Wnts have been shown to induce myogenesis and are
thought to synergistically act with Shh. Interestingly, Wnt-1 induces Myf5 expression
whereas Wnt-7a, which is expressed in the lateral plate mesoderm, induces MyoD
expression. These results confirm previous studies demonstrating that the neural tube
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induces Myf5 expression while the dorsal ectoderm preferentially activates MyoD
expression.
The BMPs belong to the TGF-beta family of secreted factors and information obtained
thus far shows that these factors negatively regulate myogenesis. Recent experiments
strongly suggest that BMP concentration gradients are vital for cells to respond
appropriately. Low BMP levels in the limb bud maintain migrating, Pax3 expressing
myogenic precursor cells in a proliferative state and repress myogenesis. By contrast,
high BMP concentrations induce cell death. Important aspects of BMP signaling are the
patterns of expression of BMPs and their inhibitors follistatin, noggin and chordin.
Expression of the BMP antagonist, noggin, in the DML and lateral plate regulates the
development of both medial and lateral myogenic lineages (Marcelle et al., 1997).
Indeed, ectopic expression of noggin in the lateral regions of the embryo represses Pax3
expression, expands the MyoD expression domain and induces myogenesis.
Several FGF and TGF-beta family members have also been implicated in myogenesis.
Treatment of cultured myoblasts with these factors suggests they act to stimulate
proliferation and repress terminal differentiation. However, in vivo these molecules are
important for the formation and terminal differentiation of the dorsal myotome.
Neutralizing antibodies to TGF-beta or basic-FGF (bFGF) inhibit myotomal induction by
axial structures. Exposure of segmental plate explants to a combination of TGF-beta and
bFGF induces myotome formation. TGF-beta acts to specify the cells to the myogenic
lineages whereas bFGF acts to promote proliferation and cell survival.
2.7.2 Myogenic signals in Xenopus
XmyoD expression in gastrula embryos corresponds precisely to the muscle progenitors
that form the somitic myotome. Previous studies showed that the induction of MyoD
transcription is limited to a small time window that starts after dorsal lip formation
(Steinbach et al., 1997; Steinbach et al., 1998; for review see Rupp, et al, 2002). During
gastrulation, antagonistic signals emanating from the dorsal and ventral marginal zones
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specify the full range of mesodermal derivatives along the dorsal-ventral axis (Harland &
Gerhart, 1997). Additional local “community effect” signals are required to maintain
XmyoD expression and promote cell differentiation (Gurdon, 1988; Gurdon, et al., 1992,
Kato and Gurdon, 1993; Standley et al., 2001). The gene regulatory pathways for
mesoderm induction have been connected to the FGF, Wnt, BMP and activin signaling
pathways that control XmyoD and X m y f 5 activation for the specification and
differentiation of myotomal progenitors.
FGF signaling is required for the expression of many mesodermal genes (Amaya et al.,
1991, 1993; Lombardo et al., 1998; Schulte-Merker & Smith, 1995; Slack & Isaacs,
1994). Inhibition of FGF signaling in whole embryos results in a dramatic lost of
posterior tissues including somites and, thus, muscle (Amaya et al., 1991, 1993).
Embryonic FGF (eFGF) has been shown to be sufficient for the expression of XmyoD
(Fisher et al., 2002), and can act as a community effect signal to maintain high-level
XmyoD expression and promote muscle differentiation in dispersed cultures of mesoderm
cells isolated from the early gastrula embryos (Standley et al., 2001).
XWnt8 is co-expressed with XmyoD in the mesoderm at early gastrula stages.
Overexpression of XWnt8 during gastrula stages leads to ectopic XmyoD activation across
the dorsal midline, where its expression normally is excluded, changing notochord
progenitors into myogenic progenitors (Christian & Moon, 1993). Furthermore,
dominant-negative forms of XWnt8 inhibit XmyoD expression in the early mesoderm
(Hoppler et al., 1996), whereas overexpressed ß-catenin increases XmyoD expression,
establishing ß-catenin as the effector molecule of XWnt8-mediated XmyoD activation
(Hamilton et al., 2001).
BMP signaling also interacts with XWnt8 in the control of XmyoD. BMP4 controls the
ventral expression of the Wnt antagonist, sizzled, which functions together with the
dorsally expressed Wnt inhibitor, FrzB , to localize Wnt signaling to the lateral
mesoderm, enhancing XmyoD expression and muscle progenitor formation (Marom et al.,
1999). The timing and spatial localization of Xmyf5 and XmyoD expression in myogenic
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progenitors differs, presumably reflecting their control by different signals or
combinations of signals. Whereas it has been demonstrated that ß-catenin-mediated Wnt
signaling is necessary for the normal expression of Xmyf5 and XmyoD (Hamilton et al.,
2001; Shi et al., 2002), BMP signaling has both a positive and a negative role in Xmyf5
regulation. Overexpression of a dominant-negative BMP4 receptor in embryos abolishes
its expression, and low levels of BMP4 signaling can induce ectopic Xmyf5 expression
(Dosch et al., 1997). BMP4 can also repress Xmyf5, restricting its expression to the dorsal
most mesoderm. Inhibition of BMP activity by dorsally expressed BMP antagonists, i.e.
Noggin, Chordin and Follistatin, creates a dorsal-ventral gradient of BMP signaling that
localizes Xmyf5 expression to the dorsal lateral mesoderm of the embryo where muscle
progenitors form (Re’em-Kalma et al., 1995).
Activin has also been shown to be sufficient to induce the expression of XmyoD in animal
cap (AC) assay (Steinbach et al., 1997; Steinbach et al., 1998). To date, no cis-regulatory
element of XmyoD has been characterized to mediate transcription induction by any of
these MIFs. Therefore, the experimental data is still not enough to conclude any of these
factors is a direct or indirect input.
2.8 Preliminary work on the transcriptional regulation of the XmyoDb gene in
Xenopus
In order to study the regulation of XmyoD, our lab screened a Xenopus laevis genomic
library using a promoter specific probe. One positive clone was isolated which contained
10.8 kb of sequences flanking the XmyoDb gene (Figure 2.6A) from position -6 kb up to
position +4829 bp (Steinbach and Rupp, unpublished). Sequence data reveal that the
XmyoDb locus contains three exons, which is in agreement with previous data (Leibham
et al., 1994). For analysing the cis-elements of the XmyoDb gene, a GFP reporter gene
was cloned into the 5`UTR of XmyoD gene at position +107 (Figure 2.6A) and based on
this clone other deletion constructs were made.
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Initial attempts to study the transcriptional activity of XmyoD reporter genes by episomal
DNA-microinjection failed to produce specific and consistent results. The injected
embyros showed mosaic and ectopic expression of GFP (Otto, 2001 and Figure 2.6B, j).
Figure 2.6 Transgenic reporter gene analysis for XmyoD. A) Schematic representation of the
XmyoD locus and the pMD-6.0kb/+4829GFP report plasmid. Black boxes represent the three
exons, while red box represent GFP gene. The arrow indicates the transcriptional start site. (B)
RNA in situ hybridization analysis. The expression pattern of endogenous XmyoD mRNA (a-c)
in albino embryo and pMD-6.0/+4.7GFP plasmid (d-g) in transgenic frog embryos at different
stages. The section along D-V axis showed that the signal is restricted in the ventral mesodermal
cells (insert in e), a black arrow indicates the dorsol lip and a red arrow highlights the in situ
hybridization signal.  (g) Section showed the expression was only in somite muscle tissue
(arrow).  Ectopic activation of the reporter gene by injected bFGF/Xwnt8 mRNA reflects the
timing of induction of the endogenous XmyoD gene (compare d,e with h, i). The embryos are
orientated with dorsal pointing up and vegetal pole facing out (a,b,d,e), or animal pole facing out
(h, i) or head facing left (c, f, j). (Xiao, L., Otto, A. and Rupp, R., unpublished data)
2. Introduction
20
We reported before that chromatin components play a pivotal role in regulating XmyoDb
transcription (Steinbach et al., 1997). Therefore, we decided to use the transgenesis
technique developed by Kroll and Amaya (1996) to introduce GFP reporter constructs
into the embryos through restriction enzyme mediated integration (REMI). Because at the
gastrula stages, GFP fluorescence intensity was too low to be recorded consistently, and
GFP protein is too stable to report the changes of XmyoD expression pattern, we
documented GFP expression by in situ hybridization in transgenic embryos, and
compared the expression pattern with that of endogenous XmyoD mRNA in wild-type
embryos (Figure 2.6B, a-c). Transgenic embryos containing the full-length reporter
construct showed XmyoD-like expression during development, i.e., no expression at the
onset of gastrulation (NF10), U-shape expression at midgastrula stage (NF10.5) and
somite-specific expression at tailbud stages (Figure 2.6B, d-f). Sectioning of these
transgenic embryos confirmed that the expression of GFP is restricted to the mesoderm at
stage NF10.5 (Insert of Figure 2.6B, e) and to somite at tailbud stages (Figure 2.6B, f and
g).
Previous studies showed that the activation of XmyoD expression is limited to a small
time window that starts after dorsal lip formation (Steinbach et al., 1997; Steinbach et al.,
1998; for review see Rupp, et al, 2002). So we asked if the full-length reporter construct
does reflect this temporal restriction. To assess this question, transgenic frog embryos,
containing the plasmid pMD-6.0kb/+4829GFP, were generated and the cleaving ones
were injected with a combination of FGF/Wnt8 mRNA at the 4-cell stage into the animal
pole. Under this condition, the reporter gene was activated in the same time window as
the endogenous gene (Figure 2.6B, h-i). Therefore, it was concluded that the 10.8 kb
contig is sufficient to recapitulate the dynamic stage- and tissue-specific expression
pattern of XmyoD in transgenic embryos, and therefore it must contain most of cis-
regulatory elements that controll XmyoD transcription (Otto, 2001).
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2.9 The aim of this work
As mentioned above, so far, the regulatory mechanisms of the muscle program
downstream of XmyoD has been analyzed relatively well, but not the regulation of the
XmyoD gene itself. So the aim of the study presented here was to analyze the
transcriptional regulatory mechanism of XmyoD gene in Xenopus.
In Xenopus, the activation of the myogenic determination factor XmyoD in the muscle-
forming region of the embryo occurs in response to mesoderm-inducing factors (MIFs).
Different members of the FGF, TGF-ß, and Wnt protein families have been implicated in
this process (Steinbach et al., 1998), but how MIFs induce XmyoD is not known. We
expect that the study of the transcriptional regulatory mechanism of XmyoD will help us
to understand how the muscle linage is specified, and also provide insight into
mesodermal patterning.
In order to address the transcriptional regulatory mechanisms of the XmyoD gene, I
decided to use two approaches:
1.   Mapping of the XmyoDb  cis-regulatory elements
I used the transgenesis technique, developed by Kroll and Amaya (1996), to introduce
GFP reporter constructs with serial deletion of genomic fragments from the XmyoD
gene into the embryos through restriction enzyme mediated integration (REMI).
Expression of GFP at various developmental stages were detected by in situ
hybridization of GFP mRNA in REMI-embryos, and the expression pattern was
compared with that of endogenous XmyoD mRNA in normal embryos; Fine mapping
of cis-regulatory elements was accomplished by linker-scanner mutagenesis.
2.   Potential protein factors that regulate the expression of XmyoD gene
The main methods I used were gain-of-function and loss-of-function assays to
analyze the function of potential protein factors that may regulate the expression of
XmyoD gene.
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3 Material and methods
3.1 Reagents
Fine chemicals: Fluka, Merck, Sigma, USB.
Bio-chemicals: Agar (Difco); Agarose (Gibco/BRL); Ampicillin, Streptomycin, Bacto
trypton, Yeast extract (Difco); Chicken serum, lamb serum (Gibco/BRL); Human
choriongonadotrophin (Sigma); Levamisol (Vector Laboratories).
Enzymes and proteins: Alkaline phosphatase (Roche); BSA fraction V, Chymostatin,
Leupeptin, Pepstatin (Sigma); DNase I (Stratagene); Klenow enzyme (Roche); MMTV
reverse transcriptase (Gibco/BRL); Restriction endonuclease with 10x restriction buffer
system (New England Bio Labs, Roche, Fermentas); RNaseA (Sigma); RNAsin
(Promega); T3, T7 and SP6 RNA polymerase with 5x incubation buffer (Promega); Taq
DNA polymerase with 10x PCR buffer (Perkin Elmer); Pfu polymerase with 10x PCR
buffer (Stratagene); Proteinase K (Sigma); RNAse free DNAse I (Promega); Pre-stained
protein molecular weight standard low and high range (Gibco/BRL).
Immunochemicals: Sheep anti-mouse IgG coupled with alkaline peroxidase (1:5000,
Roche); Monoclonal mouse anti-Myosin heavy chain (MHC) (MF20, 1:5 (Bader et al,
1982)); Sheep anti-Digoxigenin Fab fragment coupled with alkaline phosphatase
(Roche); BM Purple solution (Roche).
3.2 Devices
Gel filtration columns QuickSpin G-50 (Roche).
Glass injection needles: Glass 1BBL W/FIL 1.0 mm (World Precision Instrument).
Injection equipment:
Injector Pli-100 (Digitimer Ltd.).
Incubator: Driblock DB1 and DB20 (Teche).
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Microneedle Puller P-87 (Sutter Instrument).
Micromanipulator: Mm-33 (Science Products).
Microscopes: Stereomicroscopes Stemi SV6 and Stemi SV11 (Zeiss).
Microsurgery: Gastromaster (Xenotek Engineering).
Nylon membran: HybondTM N (Amersham).
Software: Adobe Photoshop 6.0; Illustrator 9.0 (Adobe); McVector 6.0 (Oxford
Molecular Group); Microsoft Office 98 (Microsoft).
Spectrophotometer: GeneQuant II (Pharmacia Biotech).
Thermocycler: Primus 96 plus (MWG).
Centrifuges: Eppendorf centrifuge 5417C (Eppendorf); Omnifuge 2.0 RS (Haereus);
Sorvall RC-5B (Du Pont).
3.3 Nucleic acids
3.3.1 Size standard
DNA standard: GeneRuler™ 1kb DNA ladder (Fermentas). The DNA ladder yields the
following 14 discrete fragments (in base pairs): 10000, 8000, 6000, 5000, 4000, 3500,
3000, 2500, 2000, 1500, 1000, 750, 500, 250.
3.3.2 Oligonucleotides
All Oligonucleotides were synthesized by the company MWG Biotec.
3.3.2.1 Oligonucleotides for RT-PCR
 Xenopus Histon H4 (Niehrs et. al, 1994):
OS1 (sense): 5' - CGG GAT AAC ATT CAG GGT ATC ACT -3 '
OS2 (anti-sense): 5 ' - ATC CAT GGC GGT AAC TGT CTT CCT -3 '
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Random Hexamer:
RR13: 5' - NNNNNC -3 ' (N = G, A, T or C)
Xenopus myoDb (position 662-952, Hopwood et. al, 1989)
RR23 (sense): 5' - AAC TGC TCC GAT GGC ATG ATG GAT TA -3 '
RR24 (anti-sense): 5 ' - AATT GCT GGG AGA AGG GAT GGT GAT TA -3 '
3.3.2.2 Oligonucleotides for cloning
Oligo Sequence Position in MD-3200/+4829
XL18 GCGCCCGCGGCTGAGCAGCTACAGGCAAACTG 36-57
XL24 AGGCCTCCCCTTGTGTCCGTGTCTACTC 1713-1734
XL28 GGGGAGGCCTGTGGCCCCCATACTCGGAGG 1742-1761
XL41 GGGGCTCGAGAGATCCACAGCTCTGGGGTCC 3304-3324
AO58 CACGGTGGAAGCTTTCTCCCT
AO65 TCCCCGCGGCAGTTGGTGTAGTTG
AO95 CCGCTCGAGCCTGCCTCCTGCTGGT 3’UTR
AO96 CCGCTCGAGGCCCTTGGGATAAGATTT 3’UTR
XL204 GTTTGTTTAACTGACAAATTCCTG 1916-1939 of MDfl
XL205 GGTGTAGTTGCTGGGGGTAC R&C of 1096-1120 of MDfl
XL206 CAGGAATTTGTCAGTTAAACAAAC 1096-1120 of MDfl
XL207 ACCCCCAGCAACTACACCAAC R&C 1916-1939 of MDfl
3.3.2.3 Oligonucleotides for mutagenesis
Oligo Sequence Mutation
XL37 CCCCTATCCTATCACAAACCTCACAAGTCACAGGAGGGTC
pMD∆-1.2/-
0.9GFP
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XL38 GACCCTCCTGTGACTTGTGAGGTTTGTGATAGGATAGGGG
pMD∆-1.2/-
0.9GFP
XL39 GACTATTAACCCACTGTTACCTCACTTCCCACCCAGGAG
pMD∆-1.8/-
1.2GFP
XL40 CTCCTGGGTGGGAAGTGAGGTAACAGTGGGTTAATAGTC
pMD∆-1.8/-
1.2GFP
dRE2a CCTTCCTTTCCTAGGCCTGGTAGTTTAACCCCTG
pMD∆-1.8/-
1.6GFP
dRE2b CAGGGGTTAAACTACCAGGCCTAGGAAAGGAAGG
pMD∆-1.8/-
1.6GFP
Linker AGACTGGGCCCTGTG
XL43 CCTACAATGAAGCGAATCTGAAAGACTGGGCCCTGTGCACAGGAGGGTCTCACATATTC LS-1
XL44 GAATATGTGAGACCCTCCTGTGCACAGGGCCCAGTCTTTCAGATTCGCTTCATTGTAGG LS-1
XL45 GAATCTGAATCTAGTGTCACAAGTAGACTGGGCCCTGTGCATATTCTTGTGTGTTTCACTTG LS-2
XL46 CAAGTGAAACACACAAGAATATGCACAGGGCCCAGTCTACTTGTGACACTAGATTCAGATTC LS-2
XL47 CAAGTCACAGGAGGGTCTCAAGACTGGGCCCTGTGTTCACTTGTAGATAAGACTTGAAAG LS-3
XL48 CTTTCAAGTCTTATCTACAAGTGAACACAGGGCCCAGTCTTGAGACCCTCCTGTGACTTG LS-3
XL49 GGTCTCACATATTCTTGTGTGTAGACTGGGCCCTGTGGACTTGAAAGGGAATCTCTGAG LS-4
XL50 CTCAGAGATTCCCTTTCAAGTCCACAGGGCCCAGTCTACACACAAGAATATGTGAGACC LS-4
XL69 CTTGTGTGTTTCACTTGTAGATAAAGACTGGGCCCTGTGCTCTGAGGAAGTTGAATTAAATTAGG LS-5
XL70 CCTAATTTAATTCAACTTCCTCAGAGCACAGGGCCCAGTCTTTATCTACAAGTGAAACACACAAG LS-5
XL71 GTAGATAAGACTTGAAAGGGAATAGACTGGGCCCTGTGATTAAATTAGGAAATTAGCACTTAGC LS-6
XL72 GCTAAGTGCTAATTTCCTAATTTAATCACAGGGCCCAGTCTATTCCCTTTCAAGTCTTATCTAC LS-6
XL121 CTCTGGCTTTGATGTGGGCATAATTTGGCATTTGCAGGAAG mSRE CC-CA
XL122 CTTCCTGCAAATGCCAAATTATGCCCACATCAAAGCCAGAG mSRE CC-CA
XL123 GTGGGCCTAATTTGGCATTAGCAGGAAGGTGCCGCGTTAATAATG mE TG-AG
XL124 CATTATTAACGCGGCACCTTCCTGCTAATGCCAAATTAGGCCCAC mE TG-AG
XL148 CTCTGGCTTTGATGTGGGCCTTATTTGGCATTTGCAGGAAGGTGC mSRE AA-TA
XL149 GCACCTTCCTGCAAATGCCAAATAAGGCCCACATCAAAGCCAGAG mSRE AA-TA
XL156 GCTTTGATGTGGGCCTAATTTTTCATTTGCAGGAAGGTGCCGC mSRE GG-TT
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XL157 GCGGCACCTTCCTGCAAATGAAAAATTAGGCCCACATCAAAGC mSRE GG-TT
XL158 GGGAATCTCTGAGGAAGTTGAAGACTGGGCCCTGTGTAGCACTTAGCTCTGGGACTCC LS-7
XL159 GGAGTCCCAGAGCTAAGTGCTACACAGGGCCCAGTCTTCAACTTCCTCAGAGATTCCC LS-7
XL160 GGAAGTTGAATTAAATTAGGAAATAGACTGGGCCCTGTGGGACTCCCGGTACCAAGCG LS-8
XL161 CGCTTGGTACCGGGAGTCCCACAGGGCCCAGTCTATTTCCTAATTTAATTCAACTTCC LS-8
XL162 GGAAATTAGCACTTAGCTCTGAGACTGGGCCCTGTGAGCGAAATCTTTGGGATCCCAGAAG LS-9
XL163 CTTCTGGGATCCCAAAGATTTCGCTCACAGGGCCCAGTCTCAGAGCTAAGTGCTAATTTCC LS-9
XL164 CTCTGGGACTCCCGGTACCAAGACTGGGCCCTGTGATCCCAGAAGGTGCGAATG LS-10
XL165 CATTCGCACCTTCTGGGATCACAGGGCCCAGTCTTGGTACCGGGAGTCCCAGAG LS-10
XL185 GCGTTAATAATGAGTTTTTAGCTTCTGGGATCCAGCAAGTTCTATGGTCACAGGAG
mFAST site in
 –1.8/-1.6kb
XL186 CTCCTGTGACCATAGAACTTGCTGGATCCCAGAAGCTAAAAACTCATTATTAACGC
mFAST site in
 –1.8/-1.6kb
XL187 CAGGAGATGACAAGAGCCTCTGGGGATCCTGTGGGCCTAATTTGGCATTTGC
mLEF in
 –1.8/-1.6kb
XL188 GCAAATGCCAAATTAGGCCCACAGGATCCCCAGAGGCTCTTGTCATCTCCTG
mLEF in
 –1.8/-1.6kb
XL210 CTGGCAAATGGAAATTAAACGAAAGGATCCCTCTGGGGCCCCCCAGCC
mLEF in
promoter
XL211 GGCTGGGGGGCCCCAGAGGGATCCTTTCGTTTAATTTCCATTTGCCAG
mLEF in
promoter
3.3.3 Plasmids
3.3.3.1 Plasmids for in vitro transcription
Plasmid Linearized by Polymerase Reference
pSP64TXeFGF Acc I SP6 Isaacs  et al., 1994   
pCS2+Xcad3 Not I SP6 Isaacs   et al., 1998
pCS2+Xcad3-VP16 Not I SP6 Isaacs   et al., 1998
pCS2+Xcad3-EnR Nsi I SP6 Isaacs   et al., 1998
pCS2+mtXSRF Not I SP6 Oliver Nentwich, Nordheim Lab
pCS2+XSRF1-350EnRmt Ehe I SP6 Oliver Nentwich, Nordheim Lab
pCS2+MT6 Xseb4-WT Not I SP6 Rupp Lab
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pCS2+MT6 Xseb4-∆N Not I SP6 AA50, Rupp Lab
pCS2+MT6 Xseb-∆C Not I SP6 AA48, Rupp Lab
pCS2+MT6 long mSeb4 Not I SP6 AA55, Rupp Lab
pCS2+MT6 short mSeb4 Not I SP6 AA56, Rupp Lab
pCS2+EnR-YY Not I SP6 Satijn et al., 2001
3.3.3.2 Plasmids for dig-labeled RNA in situ hybridization probes
Plasmid Linearized by Polymerase Primers References
pRR3 (XmyoDb) Hind III T7 Antisense probe
pCS2+GFP2 BamH I T7 Antisense probe
TOPOII XLC04 Not I SP6 XL18, XL24 Sense probe
TOPOII XLC04 Hind III T7 XL18, XL24 Antisense probe
TOPOII XLC09 Apa I SP6 XL28, XL41 Sense probe
TOPOII XLC09 Sac I T7 XL28, XL41 Antisense probe
TOPOII XLC14 Not I SP6 No Document
TOPOII XLC14 Hind III T7 ND
TOPOII XLC15 Not I SP6 ND
TOPOII XLC15 Hind III T7 ND
TOPOII XLC16 Not I SP6 XL204, XL18 ND
TOPOII XLC16 Hind III T7 XL204, XL18 ND
TOPOII XLC17 Not I SP6 XL205, XL24 ND
TOPOII XLC17 Hind III T7 XL205, XL24 ND
TOPOII XLC18 Not I SP6 XL206, XL207 ND
TOPOII XLC18 Hind III T7 XL206, XL207 ND
Xnot10 Hind III T7 von Dassow et al., 1993
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XpoHK Hind III T7 Sato and Sargent, 1991
3.3.3.3 Reporter gene constructs
Plasmid Primers Template Contructed by
pMD-2100/+4829 GFP AO58, AO65 pMD-3200/+4829GFP Digested by SacII and
Hind III
pMD-3200GFP3'UTR AO95, AO96 pMD-3200/+4829GFP Digest by Xho I
pMDD-1770/-1200GFP XL39, XL40 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDD-1200/-840GFP XL37, XL38 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDD-1770/-1586GFP dRE2A, dRE2b pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS1 XL43, XL44 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS2 XL45, XL46 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS3 XL47, XL48 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS4 XL49, XL50 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS5 XL69, XL70 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS6 XL71, XL72 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS7 XL158, XL159 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS8 XL160, XL161 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS9 XL162, XL163 pMD-3200/+4829GFP Site-Directed Mutagenesis
pMDLS10 XL164, XL165 pMD-3200/+4829GFP Site-Directed Mutagenesis
mSRE AA-TA XL148, XL149 pMD-3200/+4829GFP Site-Directed Mutagenesis
mSRE CC-CA XL121, XL122 pMD-3200/+4829GFP Site-Directed Mutagenesis
mSRE GG-TT XL156, XL157 pMD-3200/+4829GFP Site-Directed Mutagenesis
mE TG-AG XL123, XL124 pMD-3200/+4829GFP Site-Directed Mutagenesis
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3.3.3.4 Plasmids for transgenesis
Plasmid Digestion by Reference
pCS2+XSRF1-350EnRmt Ehe I Oliver Nentwich
pCSGFP2 Not I Zernicka-Goetz et al., 1996
PCS2+Lef-1-VP16 Not I Yang et al., 2002b
PCS2+Lef-1-EnR Asp 718 Yang et al., 2002b
3.4 Bacteria manipulation
Preparation of competent cells and transformation have been performed according to
standard methods (Sambrook et al., 1989).
3.5 Embryological Methods
3.5.1 Solutions
Cystein: 2% L-Cystein in 0.1x MBS (pH 7.8 at 23°C, adjusted with 5 M NaOH).
Human Choriongonadotropin (HCG): 1000 I.U./ml HCG in ddH2O.
MEMFA: 0.1 M MOPS, 2 mm EGTA, 1 mm MgSO4; 3.7% formaldehyde (pH 7.4 at
23°C).
1xModified Barth’s Saline (MBS): 5 mm HEPES, 88 mm of NaCl, 1 mm of KCl, 0.7 mm
CaCl2, 1 mm MgSO4, 2.5 mm NaHCO3 (pH 7.6 at 23°C). Add the CaCl2 before use.
0.1xMBS/Gentamycin: 0.1xMBS +10 ug/ml Gentamycin, in cell culture water.
0.5xMBS/BSA: 0.5 x MBS, 1mg/ml BSA, 10 ug/ml Gentamycin, in cell culture water.
0.5xMBS/CS: 0.5 x MBS with 20 % chicken serum, stored at -20°C.
1xMarc’s Modified Ringer’s Solution (MMR): 0.1 M NaCl, 2 mm of KCl, 1 mm MgCl2,
2 mm CaCl2, 5 mm HEPES (pH 7.5 at 23°C)
0.1xMMR: 0.1xMMR + 10 ug/ml Gentamycin, desolved in medium water.
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0.1xMMR/Ficoll: 0.1xMMR, 6 % (w/v) Ficoll, 10 ug/ml Gentamycin, desolved in cell
culture water.
0.4xMMR/Ficoll: 0.4xMMR, 6 % (w/v) Ficoll, 10 ug/ml Gentamycin, desolved in cell
culture water.
3.5.2 Experimental animals
Adult wild-type (Nasco) and albino (Xenopus I) Xenopus laevis frog were used. The
frogs were held with a water temperature of 16-19°C and a population density of 5 L
water per frog. Feeding takes place three times weekly.
3.5.3 Superovulation of the female Xenopus laevis
Xenopus laevis females were stimulated to lay eggs by injection of 500 units of human
chorionic gonadotropin (Sigma) into the dorsal lymph sac and incubate at 15-23 °C over
night. Egg laying started about 12 hours later.
3.5.4 Preparation of testis
A male was anaesthetized in 0.1 g 3-Aminobenzoesaeureethylester per 100 ml ddH2O for
20 min, cooled down in ice and killed by decapitation. The two testes were taken from
the abdominal cavity by opening and pulling the yellow fat body, with which they are
connected by connective tissues. Before use the testis were stored in MBS/CS plus
antibiotics for maximal 7 days.
3.5.5 In vitro fertilization of eggs and culture of the embryos
In vitro fertilization was performed by mincing a piece of testis and mixing it with
freshly-laid eggs. Afterwards they are cultured in 0.1 x MBS at 15-23°C in 110 mm Petri
plates.
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3.5.6 Dejelly with cystein solution
In order to prepare eggs for the injection with DNA or mRNA (A) or for the generation
of transgenic embryos (B), after approx. 1 hpf (A) or after the ovulation (B) the jelly coat
should be removed in a 2% cystein buffer for 5 min under agitation. Embryos were then
washed three times with 0.1x MBS and were cultured in 0.1 x MBS (0.4 x MMR for (B))
at 15-23°C.
3.5.7 Injection of embryos
The glass injection needles were pulled with Microneedle Puller (Sutter Instrument,
model P-87). They were filled with 1-2 µl nucleotide acid containing solution shortly
before the injection. The needles were placed into the holder of the injection equipment
(Medical System, model Pi-100). Adjusting the injection volume was done via gradual
breaking of the needle tip and choice of the injection pressure and/or the injection
duration. Totally 2.5 to 10 nl nucleotide solution was injected per embryo. Embryos were
generally injected at 2-8-cell stage. After injection, embryos were incubated in 0.1X
MBS at 15-23 °C until the desired developmental stages. The medium was changed every
day to increase survival.
3.5.8 Preparation of explants
For the preparation of explants, injected embryos were transferred in 3 cm cell culture
dishes covered with 1% agarose, medium was 0.5 x MBS with BSA. Afterwards the
animal caps were taken with Gastromaster (Xenotek Engineering) and transferred
individually into a 96-well plate covered with 50 µl 1% Agarose and filled with 0.5 x
MBS.
3.6 Histological methods
3.6.1 Solution
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AP buffer: 100 mM Tris HCl (pH 9.5), 50mM MgCl2, 100 mM NaCl, 0.1% Tween 20, 5
mM Levamisole.
AP staining solution: 4.5 µl NBT, 3.5 µl BCIP in 1 ml AP buffer.
MEMFA: 0.1 M MOPS, 2 mm EGTA, 1 mm MgSO4, 3.7% formaldehyde (pH 7.4 at
23°C).
PBS: 137 mm of NaCl, 2.7 mm of KCl, 8 mm Na2HPO4, 1.7 mm KH2PO4 (pH 7.2 at
23°C).
PBT: PBS plus 2 mg/ml BSA plus 0.1% (v/v) triton-X-100.
X-Gal: 1 mg/ml X-Gal in DMF.
X-Gal staining solution: 50 mm K3Fe(CN)6, 50 mm K4Fe(CN)6, 1 mg/ml X-Gal
(dissolved in DMF) in X-Gal Washing buffer.
X-Gal washing buffer: 0.1 M phosphate buffers, 2 mm MgCl2, 0.1% sodium
desoxycholat, 0.02% (w/v) NP40 (pH 7.3 at 23°C).
3.6.2 Fixation of embryos
Embryos were fixed in MEMFA for 1 h under rotation on a vertical wheel. The Embryos
was washed 2 times with PBS. Embryos for the immunohistochemistry were finally
washed with methanol. Embryos for in situ hybridizing were incubated for several hours
in 100% ethanol.
3.6.3 Immunocytochemistry
1. Fix embryos in MEMFA for one hour at room temperature with rotation. Rinse
with PBS, replace with methanol.
2. Rehydrate by 80%, 50%, 0% methanol in PBS. Do 1 x 5 min wash with PBS.
3. Wash in PBT for 15 min.
4 .  Block protein binding sites by incubating embryos in PBT plus 10% heat
inactivated goat serum at room temperature for 15-30 min.
5. Remove blocking solution and add primary antibody (1 µl MF20 from mouse in 1
ml PBT to 1:1000 dilution), incubated overnight at 4 °C if sensitivity is not a
problem.
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6. Wash with at least five changes, 5 ml per wash, an hour (30-60') each, of PBT.
7. Block as above 15 to 30'.
8. Secondary antibody coupled with AP is added in blocking solution. Incubate at
4°C overnight.
9. Wash 5 times, 60' each, 5 ml per wash PBT.
10. Wash twice in AP buffer 5-20'.
11. Staining in 1 ml staining solution in dark.
12. After staining, wash in PBS, fix O.N in methanol and store in PBS at 4 °C.
3.6.4 LacZ staining
1. Fix embryos in MEMFA for 1 h.
2. Rinsing with 1× PBS twice for 10 min each,
3. Wash the embryos with X-gal washing solution with shaking for 3 times and 30
    min each.
4. stain for 20-120 min at room temperature until the blue color appears.
  5. Rinse the embryos with 100% ethanol twice for 5min each, afterwards store them at
     –20ºC.
3.7 SDS-PAGE and Western blotting
SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and Western blotting were carried
out according to standard protocols (Sambrook et al., 1989), and signals were detected by
enhanced chemiluminisence (Amersham).
3.8 Molecular biological methods
3.8.1 Solutions
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AB buffer: 80% (v/v) TBSX, 15% (v/v) heat-inactivated lamb serum, 5% (v/v) Xenopus
egg extract.
DEPC-H2O: ddH2O with 0.1% (v/v) Diethylpyrocarbonat (DEPC) agitated at 23°C over
night and autoclaved afterwards.
10 mm DIG NTP mixture: 10 mm CTP, GTP, ATP, 6.5 mm UTP and 3.5 mm Dig-11-
UTP.
Hybridizing solution: 5 x SSC, 50% (v/v) formamide, 1 % (w/v) Boehringer block, 0.1 %
(w/v) Torula RNA, 0.01 % Heparin, 0.1 % Tween-20, 0.1 % CHAPS, 5 mm EDTA.
Lamb Serum: Heat-inactivated lamb serum (30 min with 56°C), stored at -20°C.
MEMFA: 0.1 M MOPS, 2 mm EGTA, 1 mm MgSO4, 3.7% formaldehyde (pH 7.4 at
23°C).
PBS: 137 mm of NaCl, 2.7 mm of KCl, 8 mm Na2HPO4, 1.7 mm KH2PO4 (pH 7.2 at
23°C).
PBSw: 1 x PBS, 0.1 % Tween-20 (pH 7.5 at 23°C).
PCI: 50% (v/v) phenol, 48%(v/v) chloroform, 2% (v/v) isoamyl alcohol.
PCR buffer (Taq): 10 mm of trichloroethylene HCl, 50 mm of KCl, 1.5 mm MgCl2 (pH
8.4 at 23°C).
PCR buffer (Pfu): 10 mm of trichloroethylene HCl, 10 mm of KCl, 2 mm MgCl2, 10 mm
(NH4)2SO4, 0.1% (v/v) triton X-100, 100 ug/ml nuclease free BSA in DEPC H2O (pH 8.4
at 23°C).
5x RNA polymerase transcriptions buffer: 200 mm of trichloroethylene HCl, 30 mm
MgCl2, 10 mm of spermidin, 50 mm of NaCl (pH 7.5 at 23°C).
20 x SSC: 3 M NaCl, 0.3 M sodium citrate (pH 7.0 at 23°C).
TBS: 50 mm of trichloroethylene HCl, 150 mm of NaCl (pH 7.5 at 23°C).
TBSX: 1 x TBS, 0.1% triton X-100 (pH 7.5 at 23°C).
TE: 1 mm EDTA, 10 mm of tris HCl (pH 8.0 at 23°C).
TBE: 100 mm of trichloroethylene HCl, 83 mm borate, 0.1 mm EDTA (pH 8.6 at 23°C).
Transcription buffer: 20 mm of Tris HCl, 10 mm of Spermidin, 3 mm MgCl2, 50 mm of
NaCl (pH 7.5 at 23°C) in DEPC H2O.
Xenopus egg extract for in situ hybridization: dejelly unfertilized eggs with 2% cystein,
wash 3 times, add 1 volume of PBS then lysis by 10 strokes of a Dounce homogenisators,
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and centrifuged (7500 x g, Sorvall Rc-5b, rotors Ss-34, 10000 rpm, 4°C, 10 min). The
supernatant was transferred into a fresh centrifuge tube and recentrifuged twice under the
same conditions. The supernatant was aliquoted and stored at -20°C.
3.8.2 Isolation of nucleic acids
3.8.2.1 Mini-preparation with Qiagen kit
Plasmid DNAs mini-preparations were carried out using Qiagen mini-preparation kits .
3.8.2.2 Isolation of RNA
The embryos or explants were collected at the proper developmental stage in 1.5 ml
eppendorf tubes, 3 animal caps or 3 whole embryos in one tube. Pipette off the buffer as
much as possible and add Trizol (GibcoBRL), 30µl per explant and 100µl per embryo,
vortex for 5-10 min at room temperature. If not used immediately, Trizol samples can be
stored at -70°C. Add 2µl per 10µl of chloroform, vortex, spin 5 min at 4°C with maximal
speed. Take the upper phase, precipitate with 0.5 volume isopropanol/tRNA, mix, keep at
-20°C for at least 30 minutes. Spin at 4°C for 20 minutes. Wash the pellet with 70%
ethanol, keep at room temperature for 5-10 minutes. Spin, pour off ethanol, dry briefly,
dissolve in DEPC-treated H2O, 2 µl per explantat and 25 µl per embryo.
3.8.3 Analysis and manipulation of nucleic acids
3.8.3.1 Gel electrophoresis of nucleic acids
DNA or in vitro synthesized RNA was isolated in horizontal agarose gel. Depending
upon fragment size, 0.7 or one percent agarose gel were used. 0.5x TBE buffer was used.
After electrophoresis the gels were photographed. 1 kb DNA ladder was used as size
standard.
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3.8.3.2 Isolation of DNA fragments from agarose gel
In order to isolate DNA fragments after electrophoresis from agarose gel, the appropriate
band were cut out under long-wave UV light. The DNA was extracted from the gel with
Qiagen gel-extraction kit.
3.8.3.3 Cloning methods
The cloning of DNA has been performed according to standard methods (Sambrook et
al., 1989).
3.8.4 Polymerase chain reaction (PCR)
3.8.4.1 PCR amplification of DNA fragments for cloning
The reaction was accomplished in a total volume of 50 µl. The reaction mixture
contained 100 ng of the DNA template, 25 pmol eash primer, 0.5 mm dNTPs, 1 U turbo-
Pfu polymerase or Taq polymerase and 1x buffer. The programe is: 95ºC 1 min, 55ºC 1
min, 72ºC 1 min/kb, 35 cycles. The PCR products were digested with suitable
endonuclease, seperated on agarose gel and isolated the desired DNA fragment.
3.8.4.2 RT-PCR
In RT-PCR assay, RNA was initially reverse-transcribed to yield cDNA, the cDNA
samples were normalized by PCR amplification of housekeeping genes, such as H4
(histone 4), and then the desired target cDNA species were amplified using specific
primers. PCRs were carried out in the exponential phase of amplification and PCR
samples were loaded side by side in the agarose gel to compare their intensity.
3.8.5 In vitro transcription
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3.8.5.1 In vitro reverse transcription
A cDNA pool was generated from total cellular RNA by using of random oligo
nucleotide and reverse transcriptase (RTase) (Steinbach and Rupp, 1999). The reaction
was accomplished in a total volume of 10 µl. The reaction beginning contains 1/10
volume of total RNA, 1 x RT buffer for RTase, 10 mm DTT, 0.5 mm dNTPs, 10 U
RNAsin and 100 pmol random hexamer primers as well as 200 U RTase. The samples
was incubated at 55°C for 30 min and cooled down to 4ºC. The synthesized cDNA were
stored at -20ºC.
3.8.5.2 In vitro transcription for microinjection
Capped mRNAs used for microinjection were in vitro transcripted with RNA polymerase.
Reactions were set up as following: in a total volume of 50 µl, 2.5 ug linearized plasmid
DNA, 1 x transcription buffer, 0.5 mm dNTPs, 2.5 mm RNA cap structure analogue, 10
mm DTT, 20 U RNAsin and 40 U Sp6 or 60 U T3 or T7 RNA Polymerase, incubate at
least for 2.5 hours at 37°C. Subsequently, digeste the templates with 10 U RNAse free
DNAse I for 30 min at 37°C. The volume was filled up with DEPC ddH2O to 90 µl,
extracted and centrifuged with 1 volume of PCI (13500 x g, Eppendorf centrifuge 5415C,
14000 rpm, 23°C, 5 min). About 80 µl the supernatant was applied on the QuickSpin
column and eluted by centrifugation (1100 x g, 23°C, 4 min). The elute was again
centrifuged (13500 x g, 23°C, 5 min), and transfer supernatant into a new 1.5 ml reaction
tube and precipitate RNA with 0.1 volume of 3 M NaAc and 2.5 volume ice-cold 100%
ethanol for 20 min at -20°C. After a centrifugation (13500 x g, 4°C, 20 min), the pellet
was washed with 0.5 ml 70% ethanol, air-dried and dissolved in 10 µl DEPC ddH2O. The
concentration was determined by GeneQuant II (Pharmacia Biotech).
3.8.5.3 In vitro transcription of dig labeled RNA probes
Plasmide was linearized and generated antisense RNA by employment RNA
polymerases. The reactions were set up as following: in a total volume of 20 µl, 1 µg
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linearized plasmid DNA, 1x transcription buffer, 0.1 mm Dig NTPs, 20 U RNAsin and
20 U SP6 or T3 or T7 RNA Polymerase, incubated at 37°C for 2 h.
3.8.6 Site-directed mutagenesis
Site-directed mutagenesis is done with the QuikChange site-directed mutagenesis kit
(Stratagen, Cat. 200518) according the instruction manual. In brief (as shown in Figure
3.1), the QuickChange site-directed mutagenesis method is performed using Pfu DNA
polymerase and a temperature cycler. The basic procedure utilizes a supercoiled double-
Figure 3.1 Overview of the site-directed mutagenesis method. (Adapted from the
instruction manual of QuikChange site-directed mutagenesis kit)
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stranded DNA (dsDNA) template (50 ng) and two synthetic oligonucleotide primers (100
ng each) containing the desired mutation. The oligonucleotide primers, each
complementary to opposite strands of the vector, are extended during temperature cycling
by Pfu DNA polymerase. Incorporation of the oligonucleotide primers generates a
mutated plasmid containing staggered nicks. Following temperature cycling (96°C 1min,
55°C 1 min, 72°C 2min/kb, 20 cylces), the product is treated with DpnI. The DpnI
endonuclease (target sequence: 5´-Gm6ATC-3´) is specific for methylated and
hemimethylated DNA and is used to digest the parental DNA template and to select for
mutation-containing synthesized DNA. DNA isolated from almost all E. coli strains is
dam methylated and therefore susceptible to DpnI digestion. The nicked vector DNA
containing the desired mutations is then transformed into XL1-Blue supercompetent
cells. After the transformation, the competent cells repair the nicks in the mutated
plasmid. The small amount of starting DNA template required to perform this method,
the high fidelity of the PfuTurbo DNA polymerase, and the low number of thermal cycles
all contribute to the high mutation efficiency and decreased potential for generating
random mutations during the reaction. The mutated plasmid were conformed by
restriction enzyme digestion or sequencing.
3.8.7 RNA in situ hybridization
The Expression of mRNAs in embryos was proved by in situ hybridization.
Day 1:
 1. Rehydrate the fixed embryos in 80%, then 50% EtOH in PBSw.
 2. Wash 3x in PBSw.
 3. Treat with 10 ug/ml Proteinase K in PBSw (1 ml per vial) for 30 min at r.t.
 4. Rinse with PBSw.
 5. Wash 2x in PBSw, 5 min each
 6. Fix with 4% PFA in PBSw (0.5ml per vial). Stand for 5 min, then rock for 15'.
 7. Short rinse with PBSw.
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 8. Wash 5x in PBSw.
 9. Incubation in 50% PBSw/50% hybridization solution, followed by 100% hybridization
solution for about 3 min each step without agitation at RT.
10. Add 0.5 ml of fresh hybridization solution.
11. Prehybridization: incubate at 65°C for 1 hour.
12. Prehybridization: incubate at 60°C for 2-6 hours.
13. Heat 30 ng of probe to 95°C for 2-5 min. Add to 100 ml of prewarmed hybridization
solution.
14. Add the probe to the embryos in prehybridization solution.
15. Incubate at 60°C overnight (hybridization).
Day 2:
16. Prewarm 2xSSC/0.1% CHAPS to 37°C, and 0.2xSSC/0.1% CHAPS to 60°C.
17. Short sequential washes of embryos at 60°C with:
a) hybridization solution
b) 50% hybridization solution/50% 2xSSC/0.1% CHAPS
c) 2xSSC/0.1% CHAPS
18. Wash 2x in 2xSSC/0.1% CHAPS for 30 min at 37°C.
19. Short rinse with 0.2xSSC/0.1% CHAPS
20. Wash 2x in 0.2xSSC/0.1% CHAPS for 30 min at 60°C.
21. Rinse in 50% TBS/50% 0.2xSSC/0.1% CHAPS.
22. Wash once in TBS.
23. Rinse in TBS/0.1% Triton X-100 (=TBSX).
24. Incubate in antibody buffer (0.5 ml per vial) for 2 h at 4°C.
25. In parallel, preabsorb AP-conjugated anti-DIG antibodies (1/5000 diluted) against Xenopus
proteins present in antibody solution.
26. Add 0.5 ml of preabsorbed antibody solution to embryos (i.e. final dilution of antibodies is
10-4).
27. Incubate O. N. at 4°C.
Day 3:
3. Material and Methods
41
28. Rinse with TBSX
29. Wash 6x in TBSX for 1 hour each.
30. Rinse with AP-buffer.
31. Equilibrate in AP-buffer for 15 min.
32. Replace AP-buffer with 0.5 ml BM-Purple staining solution.
33. Incubate overnight at R.T. in dark with slight rocking (color reaction).
Day 4:
34. Stop reaction by washing twice in PBS for 10 min at R. T. with rocking.
35. Refix embryos in MEMFA for 2 hours, short rinse with H2O or PBS, store in H2O or PBS
at 4°C.
3.9 Generation of transgenic embryos by restriction enzyme meadiated integration
(REMI)
3.9.1 Introduction
Kroll and Amaya recently developed a very efficient method for generating transgenic
frog embryos (Kroll and Amaya, 1996). Briefly the protocol involves the following steps:
1. Sperm nuclei are incubated with linearised plasmid DNA. 2. After a short incubation, a
high-speed interphase egg extract and a small amount of the restriction enzyme are added
to the sperm nuclei and plasmid mixture. The extract partially decondenses the sperm
chromatin but does not promote replication and the restriction enzyme stimulate
recombination and integration by creating double stranded breaks in the sperm chromatin.
3. After the plasmid-treated nuclei are incubated for a brief period in the interphase
extract, the mixture is diluted and the nuclei are transplanted into unfertilized eggs,
resulting in the production of transgenic embryos.
3.9.2. High speed extract preparation
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The high speed extract preparation is largely based on Murray (1991). Briefly, a crude
cytostatic factor (CSF) arrested egg extract (cytoplasm arrested in meiotic metaphase) is
prepared. Calcium is added to drive the extract into interphase and a high speed spin is
performed to obtain a purer cytoplasmic fraction. Cytochalasin is omitted because it
interferes with normal development. Although a crude extract can be used for making
transgenic embryos, high speed extracts have several advantages over crude extracts.
High speed extracts promote decondensation of sperm nuclei but do not promote DNA
replication; high speed extracts cannot progress through the cell cycle; high speed extract
can be stored frozen (at -80°C) for many months before use; and sperm nuclei are more
easily mixed in high speed extracts which do not contain actin polymers.
1) The evening before the extract preparation, inject each frog with 500U HCG. The
frogs are then placed at 18-19°C overnight (12-14 hours). The next morning the egg
quality from each container is screened before mixing all the eggs and starting the extract
preparation. All the eggs released from a frog which lays mottled, lysing or dying eggs
are left out of the extract preparation.
2) All solutions should be prepared before beginning the extract preparation since the
procedure should be carried through all steps promptly once it is initiated; optimally, the
high speed spin should begin within 45-60 minutes of dejellying the eggs.
3) Overnight the frogs should have laid eggs into the 2 liters of 1X MMR. The high salt
in 1X MMR should keep the eggs unactivated and healthy. Manually expel any
remaining eggs from each frog into the 2 liter of 1X MMR. Remove the frogs and
transfer the eggs from each container into separate 500ml beakers containing around
50ml of 1X MMR. If the eggs look unhealthy, eliminate the eggs from the prep.
4) Remove as much MMR as possible from the eggs. Dejelly eggs in 2% cysteine in XB
salts (no HEPES/sucrose) at pH 7.8. Add a small amount at a time, swirl eggs, and
partially replace with fresh cysteine several times during dejellying. Dejellying should be
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performed separately for different batches of eggs and batches which show breakage or
egg activation during dejellying should be discarded.
5) Once the eggs from all the batches have been dejellied, the remaining good eggs are
pooled and washed thoroughly in XB (with HEPES/sucrose). We use about 125 ml for
each wash and do 4 washes.
6) Wash eggs in CSF-XB with protease inhibitors. We do two 35 ml washes.
7) Using a wide-bore pasteur pipette, transfer eggs into Beckman ultraclear tubes. For
these volumes, we typically use 14X95 mm tubes (Catalog #: 344060; Beckman,
Fullerton, CA 344057). If multiple tubes will be used, try to transfer an equal volume of
eggs per tube. Remove as much CSF-XB as possible and replace with about 1 ml of
Versilube F-50.
8) Spin in a clinical centrifuge at room temperature for about 60 seconds at 1000 rpm
(150g) and then 30 seconds at 2000 rpm (600 g). Eggs should be packed after this spin
but unbroken. Versilube F50 should replace the CSF-XB between the eggs and an
inverted meniscus between the Versilube and displaced CSF-XB should be clearly
visible. Remove the excess CSF-XB and Versilube F50 and then balance the tubes.
9) Spin the tubes in rubber adapters for 10 minutes at 10,000 rpm at 2°C in Sorvall HB-4
or similar swinging bucket rotor to crush the eggs. The eggs should be separated into
three layers: lipid (top), cytoplasm (center), and yolk (bottom). Collect the cytoplasmic
layer from each tube with an 18 gauge needle by inserting the needle at the base of the
cytoplasmic layer and withdrawing slowly. Transfer cytoplasm to a fresh Beckman tube
on ice. If large volumes of darkly pigmented eggs are used, the cytoplasmic layer may be
greyish rather than golden at this step. After a second spin to clarify this extract, it should
be golden.
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10) Estimate the volume of extracts and add the appropriate amount of protease inhibitors
to the isolated cytoplasm (do not add cytochalasin); recentrifuge the cytoplasm in
Beckman tubes for an additional 10 minutes at 10,000 rpm to clarify, again using a
swinging bucket rotor. Collect the clarified cytoplasm as before.Expect to get about 0.75-
1 ml cytoplasm per batch of eggs collected from one frog.
11) Add 1/20th volume of the ATP-regenerating system (Energy Mix). Transfer the
clarified cytoplasm into TL100 tubes thick wall polycarbonate tubes (Beckman 349622).
Tubes hold about 4 ml each and should be at least half full.
12) Add CaCl2 to each tube to a final concentration of 0.4mM; this inactivates CSF and
pushes the extract into interphase. Incubate at room temperature for 15 minutes then
balance for the high speed spin.
13) Spin tubes in a Beckman tabletop TL-100 ultracentrifuge in a TL100 rotor (fixed
angle) at 70,000 rpm for 1.5 hours at 4°C.
14) The cytoplasm will fractionate into four layers, top to bottom: lipid, cytosol,
membranes/mitochondria, and glycogen/ribosomes. Remove the cytosolic layer from
each tube (about 1 ml if 2-3 ml was loaded into the tube) by inserting a syringe into the
top of the tube through the lipid layer. Transfer this fraction to fresh TL-100 tubes and
spin again at 70,000 for 20 min. at 4°C.
15) Aliquot the high speed cytosol supernatant into 15 µl aliquots in 0.5ml Eppendorf
tubes. Quick freeze aliquots in liquid nitrogen and store at -80°C until use. We typically
obtain 2-3 ml of high speed cytosol from preparations of this scale. Sperm nuclei should
be incubated in an aliquot of extract and stained with Hoechst to determine whether
extract is active in decondensation. Active interphase extract should visibly swell sperm
nuclei (thicken and lengthen) within 10-15 minutes of addition to extract at room
temperature.
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3.9.3 Sperm nuclei preparation ( largely based on Murray, 1991)
1) Anaesthetise a male by immersion in 0.1% aminobenzoic acid ethyl ester (Tricaine;
MS222) (Sigma A-5040) with 0.1% sodium bicarbonate for at least 20 minutes and then
kill it. Cut through the ventral body wall and musculature and lift the yellow fat bodies to
isolate the two testes which are attached to the base of the fat bodies one on each side of
the midline. Remove the testes with dissecting scissors and place them in a 35mm tissue
culture dish containing cold 1X MMR. We routinely isolate sperm nuclei from one testis
and use the other for in vitro fertilisations. Inspect the two testes and isolate the one with
less blood contamination for the nuclear prep. If a large prep is required, testes from two
to four males can be used. The final resuspension volume should be increased
accordingly.
2) Rinse the testis in three changes of cold 1X MMR.
3) Using fine forceps, remove any remaining fat body and excess blood. Do not try to
remove the blood vessels. Rather, puncture holes in the largest vessels and gently push
the blood out. Take care not to puncture the testis as this releases sperm.
4) Place the cleaned testis in another 35mm tissue culture dish with 5 ml of cold 1X NPB
+ protease inhibitors for 2 to 5 minutes.
5) Transfer the testis to a dry 35mm tissue culture dish, and macerate the tissue well
(until clumps are no longer visible to the naked eye) with a pair of clean forceps.
6) Resuspend the macerated testes in 2 ml of cold 1X NPB + protease inhibitors by
pipetting the mixture up and down through a sterile, disposable 5 ml pipette.
7) Squirt the sperm suspension through two-four thicknesses of cheesecloth placed into a
funnel and collect the solution into a 14 ml sterile culture tube (Falcon 2059; 17 x 100
mm). Rinse the dish with an additional 3 ml of cold 1X NPB + protease inhibitors and
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add to the cheesecloth. After adding 5 ml more (10 mls total) of cold 1X NPB + protease
inhibitors use a gloved hand to fold the cheesecloth and squeeze any remaining liquid
through the funnel into the 14 ml tube. We usually end up with 9 ml of sperm suspension
in the tube.
8) Centrifuge the sperm suspension at 3,000 rpm for 10 min. at 4°C (we use a Sorvall
HB-4 or similar swinging bucket rotor fitted with the appropriate adapters). The sperm
pellet should be white, fairly compact. Usually we have some blood contamination which
can be seen in the center of the pellet. During the spin, allow 1 ml of 1X NPB + protease
inhibitors to equilibrate to room temperature.
9) Decant the supernatant and resuspend the sperm pellet in 9 ml of cold 1X NPB +
protease inhibitors and repellet by centrifugation at 3,000 rpm, 10 min., 4°C. During this
spin dissolve 1 mg of L-a-lysophosphatidylcholine (Lysolecithin) (Sigma L-4129) in 100
µl (10mg/ml) of H2O at room temperature. Lysolecithin will not remain in solution below
room temperature.
10) Decant the supernatant and resuspend the sperm pellet in the 1 ml of 1X NPB +
protease inhibitors that has equilibrate at room temperature and add 50µl of 10mg/ml
lysolecithin. Mix gently and incubate for 5 minutes at room temperature.
11) Add 10 ml cold 1X NPB +3% BSA + protease inhibitors to the suspension and
centrifuge at 3,000 rpm, 10 min., 4°C. At the end of this spin the pellet should now be
wider and more loose than before. In addition the pellet should no longer have redness.
The looseness and the loss of haemoglobin mean that the pellet now contains nuclei
rather than intact cells.
12) Decant the supernatant and resuspend the pellet in 5 ml cold 1X NPB + 0.3% BSA
(no protease inhibitors), mix gently by pipetting up and down, and centrifuge at 3,000
rpm, 10 min., 4°C.
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13) Decant the supernatant and resuspend the pellet in 250µl of 1X NPB + 30% (w/v)
glycerol + 0.3% BSA (Sperm Storage Buffer) and transfer suspension into a 1.5 ml
Eppendorf tube. Store at 4°C and use for transgenesis for up to 48 hours.
14) Cut the tip of a yellow tip with a razor blade and mix the sperm nuclei suspension by
pipetting up and down. Remove 2 µl and dilute into 200 µl of sperm dilution buffer (i.e.
1:100 dilution). Add 2 µl of a 1:100 diluted Hoechst stock and transfer the diluted sperm
nuclei to a hemacytometer for counting. Visualise the sperm nuclei under a fluorescence
microscope using a DAPI/Hoechst filter set. For a 1:100 dilution of our sperm nuclei
stock, we typically obtain counts of 125-200 (X10 4 nuclei/ml). At this concentration, the
undiluted stock contains 125-200 nuclei/nl. If your sperm stock is substantially less
concentrated (i.e.. a count of <100 for a 1:100 dilution), repellet the sperm nuclei at low
speed (or allow the nuclei to settle over a few hours) and resuspend in a smaller volume
of sperm storage buffer. We store the fresh nuclei overnight at 4°C and after extensive
mixing by pipetting up and down with a cut yellow tip, we freeze 40 µl aliquots in liquid
nitrogen and store the frozen nuclei at -80°C. One aliquot is thawed for each day of
transgenesis.
3.9.4 Preparation of DNA, needles and equipment
3.9.4.1. Preparation of linearised DNA
Digest DNA using standard conditions.
3.9.4.2 Preparation of injection needles for nuclear transplantation
These needles are unlike standard needles used for DNA and RNA injection in that the
diameter of the point is an order of magnitude larger to allow nuclei to pass through
without shearing. 30 µl Drummond micropipets (Fisher, cat. #: 21-170J) are used to make
the needles. It is important to pull needles with gentle slopes at the tip. This makes it
easier to clip the needles at the desired diameter and also they cause less damage to the
3. Material and Methods
48
eggs during transplantation. We currently use a Flaming/Brown Micropipette Puller
Model P-87 (Sutter Instruments). Clip the needle with forceps to produce a bevelled tip
of 80-100 µm diameter using the ocular micrometer of a dissecting microscope or a stage
micrometer for measurement. It is essential that the tip be this wide or nuclei passing
through will be damaged. When clipping tips, it often helps to use forceps with slightly
unmatched tips and to pull outward at a 20 or 30 degree angle from the needle as the
forceps contacts the needle. Treat the inside of needles with Sigmacote (Sigma SL-2) to
prevent shearing of sperm nuclei flowing through the needle (needles can be coated 10
minutes to several months before use). Attach approximately 1 cm Tygon tubing (R-3603
1/32”; Fisher, cat. #: 14-169-1A) to the end of a plastic pipetteman (200µl) tip and use
the pipetteman to draw up Sigmacote; then attach the other end of the tubing to the
injection needle (see below). Depress the pipetteman plunger to force Sigmacote through
the needle until a few drops emerge from the tip then release the pipetteman plunger to
withdraw most of the solution. Rinse needle with at least 200ml of water. Make sure to
remove all the liquid from the needle as any remaining liquid will block flow of nuclei
into the needle.
3.9.4.3 Agarose-coated injection dishes
Pour 2.5% agarose in 0.1X MMR into 60mm petri dishes. Before the agarose solidifies,
place small weigh boats on the agarose so that as the agarose solidifies, a square
depression in the agarose remains. The depression will accommodate ~500 eggs. Wrap
the dishes in parafilm and store at 4°C until use.
3.9.4.4 Transplantation apparatus
Most commercial injection apparatuses used for DNA and RNA injections which are
based on air pressure are unsuitable for nuclear transplantations, due to the large
difference in needle tip size. Flow through the 5 µm needle tips used for fluid injections
is controllable at fairly high pressures. However, with these standard systems it is usually
not possible to obtain an extremely low positive pressure and gentle, controlled flow
required to deliver an intact nucleus in a small volume (10-15 nl) through a 80-100 µm
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needle tip. Two people can transplant nuclei at the same time. The oil that we use to fill
the system is Mineral Oil (Embryo Tested) from Sigma (Cat. No. M-8410). The big
advantage of using an infusion pump is that we can adjust it to any desirable flow rate.
We have ours set at 10nl/sec.
3.9.4.5 Transgenesis by sperm nuclear transplantation into unfertilised eggs
1) The night before eggs are needed for transplantations, inject 2 adult female frogs in the
dorsal lymph sac with 500U Human Chorionic Gonadotropin (HCG) and incubate at
19°C for 10-12 hours. 2) Remove a 1ml aliquot of Sperm Dilution Buffer (SDB) from the
freezer and allow it to warm to room temperature.
3) Make up 500ml of 2% cysteine in 1X MMR pH 7.8 (with 5N NaOH).
4) Fill agarose coated injection dishes with 0.4X MMR + 6% Ficoll
5) Set up a reaction:
4 µl sperm stock (~4 X 10 5 nuclei)
2.5 µl linearized plasmid (100 ng/µl)
Incubate 5min at room temperature.
Meanwhile:
Obtain a 15ml aliquot of high speed extract from -80 freezer and allow to thaw to room
temperature (only takes a few minutes). Keep aliquot on ice for the day.
Make the following mixture:
18 µl SDB
2 µl extracts
2 µl 100 mM MgCl2 (add to 5 mM final at all steps to aid enzyme action)
0.5 µl of a ~1:10 dilution of Sal I or Not I to the extracts (depending on the construct).
Mix well.
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After 5 minute incubation of DNA with sperm nuclei add the extract:enzyme:MgCl2
mixture to the sperm nuclei.
Mix the reaction by gentle pipetting (using a clipped yellow tip).
Incubate 15 min. at room temperature.
6) While sperm are swelling in reaction mixture, collect eggs from the frogs and dejelly
them in 2 % cysteine hydrochloride in 1X MMR (pH 7.8 with NaOH). Wash the eggs
thoroughly in 1X MMR. Transfer dejellied eggs into agarose coated dishes containing
0.4X MMR with 6% ficoll and gentamycin. We try to fill the depression square with
eggs. After about 5 minutes in 0.4X MMR + 6% Ficoll the eggs will pierce easily.
7) After the 10-15 minute incubation with extracts, mix the sperm nuclei gently by
pipetting up and down with a cut of yellow tip. Then transfer 5 ml of mixture into 150 ml
of SDB that is already at room temperature. At this point do not mix the nuclei. Mixing at
this point is likely to shear the nuclei. Allow the sperm nuclei:extract mixture to slowing
equilibrate with the SDB over the span of a few minutes.
8) Using a piece of Tygon tubing attached to a yellow tip (as previously described for
Sigmacoting needles) draw up the dilute sperm suspension, mix gently by pipetting up
and down and then draw up the dilute sperm nuclei and detach the yellow tip from the
pippetman (try not to create or leave bubbles in the tygon tubing as these may damage
nuclei). Be careful to keep the yellow tip horizontal or the nuclei will dribble out. Now
back load a needle by attaching it to the tygon tubing and raising the angle slightly so that
the nuclei flow gently into the needle. As long as no liquid is present at the tip of the
needle the nuclei should flow easily by simple gravity. Once the needle has backfilled
completely with nuclei, detach the needle and attach it to the tygon tubing filled with
mineral oil that is connected to the Harvard Apparatus infusion pump. If two people of
injecting load another needle as before. Place the yellow tip with the remaining nuclei
aside horizontally in case you need to load another needle.
9) Transplant sperm nuclei into unfertilised eggs.
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Start the flow in the infusion pump and begin injecting eggs, keeping the needle inside
each egg for approximately one second. Move the needle fairly rapidly from egg to egg,
piercing the plasma membrane of each egg with a single, sharp motion then drawing the
needle out more slowly. The angle of the needle should be perpendicular to the
membrane surface (rather than glancing) to avoid tearing the plasma membrane. If the
needle becomes clogged with cytoplasm, bring the tip to the air-liquid interface of the
dish. Sometimes the surface tension of the interface removes the cytoplasm plug in the
end of the needle. If a needle tip is too narrow, or if it becomes partially clogged with
debris during transplantations, the injected nuclei will be damaged during transplantation,
resulting in aneuploid or haploid embryos. You can determine whether your sperm
dilution and the flow rate used for injections were appropriate by watching the first
cleavage of the transplanted eggs. If few of the eggs received a nucleus, the frequency of
cleavage will be low; one fifth to one third of our transplantations typically result in
normally cleaving embryos. Eggs that were injected with more than one nucleus will
divide at the time of first cleavage abnormally into three or four (or more) cells. Many of
these embryos will develop to blastula stages, but most fail during gastrulation; in some,
a region of the embryo will fail to cellularize and die. Eggs injected with multiple nuclei
which do gastrulate usually do so abnormally; typically, blastopore closure is incomplete
resulting in embryos that form two wings of somites and neural tissue on each side of the
exposed yolky tissue lying in the center of the trunk. This type of gastrulation failure is
common to stressed or unhealthy embryos (particularly embryos derived from ‘soft’
eggs).
10) When the embryos have reached the 4-cell stage, gently separate them from
uncleaved eggs and transfer them to a separate dish of 0.1X MMR + 6%Ficoll +50µg/ml
gentamycin. Do not be fooled by speudocleaveages. Only keep embryos that appear like
normal, healthy 4-cell embryos. We commonly culture transplanted embryos in 24-well
tissue culture dishes with about 5 embryos per well, since culturing embryos at high
density can compromise their health. It is also important to remove dying embryos
promptly since they also can compromise the health of their siblings. When embryos are
around stage 12, media is replaced with 0.1X MMR + 50µg/ml gentamycin without
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Ficoll. Because of the large needle tip used for transplantations, embryos often develop
large blebs at the site of injection. These blebs occur when cells are forced out of the hole
left in the vitelline membrane at the injection site but they generally do not affect
development. The blebs usually fall at the neurula or tailbud stages, but they can be
removed manually once the embryos have reached the late blastula stage.
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4 Results
4.1 Analysis of XmyoD cis-regulatory elements
4.1.1 The expression of XmyoD at NF10.5 is regulated by multiple elements
As the expression of pMD-6.0kb/+4829GFP recapitulates the dynamic stage and tissue-
specific expression pattern of XmyoD, it provided a basis for analyzing the cis-regulatory
elements of XmyoD expression. To resolve which regions of the pMD-6.0kb/+4829GFP
were responsible for the regulation, a series of truncation constructs were generated
(Figure 4.1A).
As shown in Figure 4.2 and Table 4.1, the pMD-704/+4829GFP construct containing
promoter proximal regions and 3’ downstream region of the XmyoD gene, did not show
any expression in mesoderm at stage NF10.5, but showed a high level of non-specific
GFP mRNA expression mainly in ectoderm (Figure 4.2A). At tailbud stages, most
transgenic embryos lost the expression (Figure 4.2B), none of the remaining embryos
showed somite specific expression. Therefore, it is concluded that the promoter region of
XmyoD is not active in mesoderm, however it is very active in ectoderm. The correct
expression of XmyoD in Xenopus needs at least a mesoderm-activation element and an
ectoderm-repression element.
The expression of pMD-840/+4829GFP was mainly restricted to the dorso-lateral domain
of the marginal zone at NF stage 10.5 (Figure 4.2C and Table 4.1). The RNA in situ
hybridization signals were quantitatively very weak. Only in a minor fraction of the
embryos did the reporter expression spread to the ventral side, as is characteristic for the
endogenous XmyoD mRNA. Importantly, with this construct the non-specific expression
of pMD-704/+4829GFP in the ectoderm was extinguished and mesoderm specific
expression was initialized. It is expected that there must be at least two motifs in the
region of -840/-704bp: one repressing element to extinguish the non-specific expression
in ectoderm and one activating element to initialize the mesoderm specific expression.
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Figure 4.1 Schematic representation of the deletion constructs. The black bars represent XmyoD
genomic DNA; Red bars represent GFP gene. The arrow indicates the transcription start site.
The extent of the 5’ and 3’ sequences from the start of transcription are shown.
When additional sequences between -2100 and -840 bp were included in the reporter
construct, GFP-positive signals extended ventrally around the blastopore on the ventral
side (Figure 4.2E and Table 4. 1). This expression pattern was very similar to the
endogenous XmyoD expression, although the average reporter gene expression level was
somewhat weaker when compared to the full-length construct (pMD-6.0kb/+4829GFP).
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Figure 4.2 The expression of the deletion constructs at different stages. The names of the construct
are indicated on the left side of the pictures, and the stage is indicated above the pictures. (A) The
pMD-740/+4829GFP did not show any expression in mesoderm at stage NF10.5, but showed a high
level of non-specific GFP mRNA expression mainly in ectoderm. At tail bud stage, most embryos
lost the expression (B). The expression of pMD-840/+4829GFP was mainly restricted to the dorsal-
lateral domain of marginal zone at NF 10.5 (C), and the expression is gone at tail bud stage (D).
When additional sequence between -2100 and -840 bp were included in the promoter, GFP-positive
signals extended ventrally and frequently surrounded the blastopore on the ventral side (E). PMD-
3200/+4829GFP was indistinguishable from pMD-6.0kb/+4829GFP (G and H). pMD∆-840/-
704GFP showed heavy reduction of the mesoderm specific expression, and incorrect expression
increase significantly (I), the expression disappeared at tail bud stage (J). The embryos are viewed
from vegetal pole with dorsal up (C, E, G, I), or laterally (A, B, D, F, H, J).
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When more upstream sequences were included in the promoter, the GFP signals
increased in strength, but the pattern did not change compared with pMD-
840/+4829GFP. pMD-3.2kb/+4829GFP was indistinguishable from pMD-
6.0kb/+4829GFP. When the 3' region was removed in pMD-3.2/3’UTRGFP construct,
the expression pattern of GFP was identical to that of pMD-6.0kb/+4829GFP at the
gastrula stage (data not shown), although staining was less intense. But at tailbud stages,
the expression was not maintained well. So 3' region was included in all other constructs.
Addition of sequence upstream of position –704 resulted on average in a much stronger
reporter expression in the mesoderm. Therefore, it is concluded that multiple activating
elements exist in the XmyoD regulatory region, and at least one repressing element to
repress expression in ectoderm. The enhancers and silencers cooperate to define the
expression domain during the development of Xenopus.
Table 4. 1 Expression of deletion constructs at stage NF10.5
Construct Correct
Expression
Incorrect
Expression
No
Expression
n Average level of
XmyoD-like
expression∗
pMD-3200/+4829GFP 77% 8% 15% 117 +++
pMD-704/+4829GFP 0% 86% 14% 59 -
pMD-840/+4829GFP 46% 6% 48% 46 +
pMD-2100/+4829GFP 67% 6% 27% 66 ++
pMD-3200/3’UTRGFP 38% 1% 61% 95 ++
pMD∆-840/-704GFP 27% 50% 23% 131 +
pMD∆-1200/-840GFP 61% 2% 31% 152 ++
pMD∆-1770/-1200GFP 51% 1% 48% 140 ++
pMD∆-1770/-1586 GFP 38% 6% 56% 143 ++
Embryos were scored as showing expression in the same pattern as the endogenous XmyoD
(correct expression), expression that does not locate in mesoderm but in ectopic place (incorrect
expression) or no expression.
∗ represents average level of XmyoD-like expression for all transgenic embryos from a given
construct. The level of expression was rated on a scale of – to +++, with – representing no
expression, while +++ representing the expression level of full length construct (pMD-
6.0kb/+4829GFP).
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4.1.2 The -840/-704 region contains both activating and repressing elements
Because multiple cis-regulatory elements exist and cooperate to control the strength of
expression, it is difficult to conclude what regions are more important than others from
the above results. In order to further narrow down the main activating motif and
repressing motif, reporter constructs were designed that contained several internal
deletions (Figure 4.1B).
The transgenic embryos of pMD∆-1200/-840GFP, pMD∆-1770/-1200GFP and pMD∆-
1770/-1586GFP did not reveal any changes of the expression pattern at stage NF10.5,
only the staining intensity was reduced slightly (Table 4.1). The reporter construct
pMD∆-840/-704GFP, however, showed a significant reduction of the mesoderm specific
expression, and at the same time an increase in incorrect expression (Figure 4.2I and
Table 4. 1). When the -840/-704bp region was added to the promoter in pMD-
840/+4829GFP, it is showed that this region is sufficient to repress the non-specific
expression in ectoderm and initiated the specific XmyoD-like expression (Figure 4.2C and
table 4.1). When the -840/-704bp region was deleted in the context of the
–3200/+4829GFP construct, although all the other regions are present, most of the
mesoderm expression disappeared and incorrect expression increased significantly.
Therefore, -840/-704 region is essential for the correct spatial induction of XmyoD.  Due
to this activity, I named this region the MIE-element (MyoD Induction Enhancer).
4.1.3 Fine-scale mapping of MIE
Based on the above results, we expected that there were at least one activating element
and one repressing element within the MIE. I further employed a linker-scanning
mutation strategy to perform an unbiased search for important DNA motifs in the MIE.
Mutations were created such that 15bp blocks of genomic sequence were replaced by a
15bp linker sequence (Kucharczuk et al., 1999; Figure 4.3A). In Figure 4.3B, the
positions of the 10 linker-scanning mutations are demarcated by vertical lines above the
sequence.
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Figure 4.3 (A) The linker sequence with a Apa I site in the middle. (B) Linker-scanning
mutations were created such that 15bp blocks of genomic sequence were replaced by a 15bp
linker sequence. Vertical lines above the sequence demarcate positions of the 10 linker-scanning
mutations. The green sequence indicates the motif for activation, and the red sequence indicates
the motif for repression.
The results of linker-scanning assay are shown in Figure 4.4 and Table 4.2. The reporter
gene expression of LS-2, LS-3, LS-6, LS-10 mutation constructs were indistinguishable
from that of the pMD-6.0kb/+4829GFP construct (Table 4. 2).
The LS-5 mutation construct resulted in significant reduction of transgenic embryos
showing reporter expression at stage NF10.5 and at tailbud stages (Figure 4.4A,B and
Table 4. 2). The remaining GFP-positive embryos showed only a very weak RNA-signal,
restricted to the dorsolateral marginal zone. This is similar to the result of the pMD∆-
840/-704GFP construct (Figure 4.2C). From this, I conclude that the DNA sequences
mutated in the LS-5 construct are required for most of the transcriptional activation input
attributed to the MIE.
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The LS-9 mutation construct resulted in precocious expression of reporter gene before
stage NF10 (85%, n=33) (Figure 4.4 C) and a stronger and expanded expression of
reporter gene at stage NF10.5 (Figure 4.4 D). The expression expanded to the posterior
wall (PW) of the neuroenteric canal (Beck, and Slack, 1998) at tailbud stages (Figure 4.4
E-F and Table 4.2). It has been shown that MyoD induction depends on the
developmental age of the induced cells, rather than on the type or time point of inducer
application (Steinbach et al, 1998 and Figure 2.6B, h, i). The precocious expression of
reporter gene before NF10 indicated that the LS-9 motif may contain an important cis-
regulatory element that controls the timing of XmyoD expression.
The reporter gene expression of LS-4, LS-7 and LS-8 constructs also showed a slight
reduction in intensity. The LS-1 construct showed a slight increase in expression
intensity. Considering there are multiple enhancers located outside of the MIE, the LS
mutants were constructed in the context of more than 8kb genomic sequence (-
3200/+4829), only 15bp exchange results in significant change of the expression. This
indicates that both LS-5 and LS-9 motifs are indispensable for the correct spatiotemporal
induction of XmyoD transcription.
Figure 4.4. LS-5 mutation construct results in a loss of most of the expression of reporter gene
(A, B); while LS-9 mutation construct resulted in precocious expression of reporter gene before
NF10 (C) and a stronger and expanded expression of reporter gene at NF 10.5 (D); The
expression expanded to the posterior wall of the neuroenteric canal (arrow in F) at tail bud stage
(E, F). The embryos are orientated with dorsal pointing up and vegetal pole facing out (A, C, D),
or head facing left (B, E, F).
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Table 4. 2 Expression of linker-scanning mutation constructs at stage NF10.5
Construct Correct
Expression (%)
Incorrect
Expression (%)
No Expression
(%)
n Average level of
XmyoD-like
expression∗
PMDLS-1 81 16 4 57 ++++
PMDLS-2 72 15 12 65 +++
PMDLS-3 66 23 11 44 +++
PMDLS-4 62 19 19 63 ++
PMDLS-5 38 38 24 45 +
PMDLS-6 69 20 10 49 +++
PMDLS-7 58 28 14 36 ++
PMDLS-8 52 19 28 42 ++
PMDLS-9 86 5 9 65 +++++
PMDLS-10 67 11 21 61 +++
Embryos were scored as showing expression in the same pattern as the endogenous XmyoD
(correct expression), expression that does not locate in mesoderm but in ectopic place (incorrect
expression) or no expression.
∗Represents average level of XmyoD-like expression for all transgenic embryos from a given
construct. The level of expression was rated on a scale of – to +++++, with – representing no
expression, while +++representing the expression level of full length construct (pMD-
6.0kb/+4829GFP).
4.1.4. MIE is essential for eFGF to active XmyoD at NF 10.5
A recent paper reported that eFGF is an inducer of XmyoD in an animal cap (AC) assay
(Fisher et al., 2002), so we asked which region in the XmyoD promoter is responsible for
the induction by eFGF.
A total of 8pg eFGF mRNA was injected into the animal pole (AP) region of wild type or
transgenic embryos at the 4-cell stage, and the expression of endogenous XmyoD or GFP
reporter gene was assayed by RNA in situ hybridization at stage NF 10.5. At this stage,
86% (n=14) of wild type embryos showed strong expression of XmyoD in the AP (Figure
4.5A and Table 4.3). Similarly, 83% (n=23) of transgenic embryos of pMD-
3200/+4829GFP construct also showed strong expression of the GFP gene in the AP
(Figure 4.5B and Table 4.3). In contrast, only 8% (n=59) of transgenic embryos of
pMD∆-840/-704GFP construct showed strong expression, the majority (92%, n=59)
showed very low or no expression of GFP gene in the AP (Figure 4.5C). Another internal
deletion construct, pMD-1770/-1586GFP, showed a moderate activation of the GFP gene
4. Results
61
by eFGF in the AP (Figure 4.5D), 60% (n=52) of the transgenic embryos showed a strong
expression of GFP in the AP. I also assayed if the LS-5 motif played a role in the
response to the induction of eFGF. In this experiment, 27% (n=30) embryos transgenic
with the LS-5 construct showed strong expression of the GFP gene in the AP under the
induction of eFGF (Figure 4.5E).
Three conclusions can be drawn from these experiment. First, that there are multiple
response elements for eFGF signaling in XmyoD regulatory region because both deletion
constructs pMD∆-840/-704GFP or pMD∆-1770/-1586GFP showed a reduction of the
activation of GFP by eFGF. Second, the -840/-704 region (MIE) is essential for the
induction of XmyoD by eFGF signal. Third, the LS-5 motif accounts for most of the
reduction caused by deletion of -840/-704bp. This indicates LS-5 motif is very important
for the induction by eFGF.
Figure 4.5 MIE is essential for eFGF to induce the reporter gene at NF 10.5.
A total of 8pg eFGF mRNA was injected in the animal pole of wild type embryos or transgenic
embryos at the 4-cell stage. The expression of either XmyoD or GFP was assayed by in situ
hybridization at NF 10.5. Wild type embryos showed strong ectopic expression of XmyoD in AP
(A), transgenic embryos of pMD-3200/+4829GFP construct (B) and pMD∆-1770/-1586GFP
construct (D) also showed ectopic expression of GFP, but transgenic embryos of pMD∆-840/-
704GFP (C) or LS-5 constructs (E) showed very low or no ectopic expression of GFP. LacZ
staining (blue) indicates the injection position of eFGF mRNA. The embryos are orientated with
animal pole facing out.
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Table 4.3 eFGF regulates the expression of XmyoD
Transgene or
Endogenous XmyoD
Strong Induction No Induction or
almost no Induction
n
Endogenous XmyoD 86% 14% 14
pMD-3.2/+4829GFP 83% 17% 23
pMD∆-840/-704GFP 8% 92% 59
pMD∆-1770/-1586GFP 60% 40% 52
LS-5 27% 73% 30
4.1.5 Xcad-3 as potential regulator of XmyoD transcription
The DNA sequences mutated in LS-5 and LS-9 were used as queries for the TRANSFAC
database (www.molsun1.cbrc.aist.go.jp) to identify potential binding sites for sequence-
specific DNA-binding proteins. No potential motif was indicated in the LS-9 region,
however, a consensus cdxA binding site was found in the LS-5 sequence. The sequence
of the oligonucleotide used for linker scanner mutagenesis does not contain any similarity
to the cdxA consensus binding site.
CdxA is a member of the caudal protein family (Margalit et al., 1993 and Pillemer et al.,
1998). The members of the Xenopus caudal protein family have previously been shown to
be downstream of eFGF signaling and act as transcriptional activators for posterior genes
(Pownall et al. 1996). Therefore, they could be candidates to mediate the activation of
XmyoD expression, which was lost upon mutation of the CdxA binding site motif by the
LS-5 mutation. To study this possibility further, mRNAs encoding wild-type Xcad3 (a
member of the caudal protein family in Xenopus), a VP16 dominate active version of
Xcad3 and an EnR dominate negative version of Xcad3 were injected unilaterally into the
lateral marginal zone at the 2-cell stage and the effect on endogenous XmyoD expression
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was analyzed by mRNA in situ hybridization. It would be expected that if Xcad3 does
directly activate XmyoD expression, the dominant active Xcad3 variant would not
negatively interfere, and perhaps hyperactivate XmyoD expression, while the dominant
negative variant would inhibit XmyoD transcription. However, with all these versions of
Xcad3, XmyoD expression was repressed (Figure 4. 6 and Table 4. 4).
There are some reports that if a protein is expressed at different stages, that is, before
MBT or after MBT, that protein may possess different functions (Hoppler et al., 1996).
To test whether or not Xcad3 played a different role after MBT, Xcad3 and Xcad3-EnR
plasmids were injected to achieve expression starting after MBT. Even under these
circumstances, Xcad3 and Xcad3-EnR repressed XmyoD expression (Figure 4. 7 and
Table 4. 4). These results imply that the observed interference was indirect. For this
reason the possible regulation of XmoyD expression by Xcad-3 was not studied further.
Figure 4.6 Xcad3 affects endogenous XmyoD expression when it is expressed before MBT by
mRNA injection. 100 pg Xcad3, Xcad3-EnR, Xcad3-VP16 mRNA were injected in LMZ
unilaterally at 2-cell stage. XmyoD gene expression was analyzed at stages NF 12.5 by whole-
mount RNA in situ hybridization. All three variants of Xcad3 repressed XmyoD expression (B-
D). As a control, injection of LacZ mRNA alone did not change the expression of XmyoD (A).
All the embryos are viewed from the dorsal side with anterior facing up. LacZ staining (blue)
indicates the injected side (also marked by red star).
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Figure 4.7 Xcad3 affects endogenous XmyoD transcription when it is expressed after MBT by
plasmid injection. 50 pg pCS2Xcad3 (A), pCS2Xcad3-EnR (B) plasmids DNA were injected in
LMZ unilaterally at 2-cell stage. XmyoD gene expression was analyzed at stages NF 12.5 by
whole-mount RNA in situ hybridization. Both Xcad3 variants repressed XmyoD expression (A,
B). All the embryos are viewed from the dorsal side with anterior facing up. Staining for
coinjected lacZ mRNA (blue) indicates injected region.
Table 4. 4 Xcad3 effects on XmyoD expression
Injection Normal or almost
 normal
Weaker and/or
more restricted
Stronger and/or
expanded
n
Xcad3-WT mRNA 100pg 2% 98% 58
Xcad3-VP16 mRNA 100pg 4% 96% 54
Xcad3-EnR mRNA 100pg 2% 98% 43
LacZ mRNA 500pg 97% 3% 61
PCS2+ Xcad3-WT plasmid 100pg 9% 91% 32
PCS2+ Xcad3-EnR plasmid 100pg 17% 74 9% 23
4.1.6 A serum response element (SRE) is essential to maintain XmyoD transcription
An SRE box and an E-box were found in -1770/-1586bp region of XmyoD regulatory
region. I hypothesize that SRF may bind with this SRE box and regulate the expression of
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XmyoD. Serum response factor (SRF) is a transcription factor, which binds to a serum
response element (SRE) associated with a variety of genes including immediate early
genes such as c-fos, fosB, junB, egr-1 and -2, neuronal genes such as nurr1 and nur77
and muscle genes such as actins and myosins (reviewed in Chai and Tarnawski, 2002).
SRF controls cell growth and differentiation, as well as muscle development and
function. Its biological function is best elucidated for myocardium. Specific cardiac SRF
transgenesis demonstrated that overexpression of SRF caused hypertrophic
cardiomyopathy in mouse and the mouse died of heart failure within 6 months after birth
(Zhang et al., 2001). Other transgenic data suggested that SRF was needed for
embryogenesis and early development (Arsenian et al., 1998). Since SRF is an important
regulator of numerous genes involved in cell growth and differentiation, including muscle
components, SRF may also play a crucial role in the regulation of XmyoD.
In order to test this hypothesis, I made the mutation in the SRE box and performed a
transgenic reporter assay and a loss-of-function assay of SRF by expression of XSRF-
EnR, a dominant negative version of XSRF.
The consensus sequence of an SRE box is CC(A/T)6GG (Chai and Tarnawski, 2002). To
test the function of this motif, I made two kinds of mutations in the context of pMD-
3200/+4829GFP: a neutral mutation (AA-TA, Figure 4.8), which does not interfere with
SRF-binding, and several mutations that abolish specific binding by SRF. These loss-of-
function mutations were generated such that the flanking CC or GG motif of the
consensus binding site were altered (Figure 4.8). At stage NF10.5, 81% (n=64) of
transgenic embryos carrying the CC-CA neutral mutation of the SRF binding site showed
the normal expression of GFP gene and 78% (n=83) of embryos still showed expression
of GFP at tailbud stages. This indicated that almost all of the embryos maintained
expression of GFP gene throughout development. At stage NF10.5, 77% (n=61) of
embryos containing the CC-CA mutation expressed GFP mRNA normally, but only 45%
(n=42) of the embryos showed expression at tailbud stages (Table 4.5). This showed that
the expression of GFP could not be maintained in 32% of the embryos of CC-CA
mutation. At stage NF10.5, 75% (n=60) of the GG-TT mutation containing transgenic
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embryos showed normal expression, but only 47% (n=97) of the embryos expressed the
reporter gene at tailbud stages. This showed that expression of the GFP gene could not be
maintained in 28% of the embryos containing the GG-TT mutation transgene.
Figure 4.8 Schematic representation of the SRE-mutation constructs. The black bars represent the XmyoD
genomic DNA, the thicker black bar represent the exons, and the red bar represents the GFP gene. The
arrow indicates the transcription start site, the green box represent the –1770/-1586 fragment. The extent of
the 5’ and 3’ sequences from the start of transcription are shown. The SRE box is shown in yellow, E box is
shown in blue. The mutations are shown in red. The names of the mutation constructs are listed on the left
side of the sequences.
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There are reports that SRE may cooperate with an E-box (Catala et al., 1995), so I also
mutated the adjacent E-box (Figure 4.8). The result showed that this E box is neither
necessary for activation nor for maintenance of expression (Table 4. 5). Therefore, it is
concluded that this SRE contributes to the maintenance of XmyoD expression. When it is
mutated, about 30% of embryos lost the maintenance of the expression of the reporter
gene, while the adjacent E-box is dispensable. Both XmyoD mRNA and protein have
short half-lives (about 30-60min. Thayer et al., 1989). Considering that the GFP mRNA
is quite stable, and therefore disappears only slowly from the embryos, which initiated
correctly reporter gene transcription at the gastrula stage, the real impact of the SRF-site
on maintenance of XmyoD transcription may be underestimated based on these statistics.
Interestingly, the SRF-box mutant CC-CG, showed a much stronger reduction of the
reporter gene expression at tailbud stages (Table 4.5). This may be due to the production
of a CG-dinucleotide, which could be a site of DNA methylation. It also implies that
methylation may play a role in the regulation of XmyoD.
Table 4. 5 SRE site is necessary to maintain the expression of the GFP
Transgene Mutation Expression at NF10.5 Expression at NF 28
Percentage n Percentage N
mSRE AA-TA 81% 64 78% 83
mSRE CC-CA 77% 61 45% 42
mSRE GG-TT 75% 60 47% 97
mSRF CC-CG 89% 36 22% 27
mE 70% 43 80% 25
4.1.7 Effects of SRF-interference analysis on XmyoD expression
To complement the SRE-mutation analysis described above, I performed loss-of-function
assays by injecting RNA coding for a dominant-negative XSRF protein variant, i.e.,
XSRF-EnR. At the 2-cell stage, 100pg XSRF-EnR mRNA or wild type XSRF mRNA
was injected into the lateral marginal zone (LMZ). The embryos were fixed at stage
NF12 and XmyoD expression was analysed by in situ hybridization. If SRF protein would
bind to XmyoD’s maintenance enhancer, i.e., the SRE, injection of SRF-EnR mRNA
should reduce XmyoD expression, preferentially at late developmental stages, or perhaps
interfere with its transcriptional induction at the gastrula stage. In contrast,
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Figure 4.9 XSRF and/or XSRF-EnR mRNA were co-injected with lacZ mRNA in LMZ
unilaterally at 2-cell stage. XmyoD gene expression was analyzed at stage NF 12 by whole-
mount RNA in situ hybridization. A) The expression pattern of endogenous XmyoD at NF12. B)
The overexpression of WT-XSRF had two effects on XmyoD expression: the expression was
repressed in the blue field where the mRNA was injected, but the expression of XmyoD was
stronger and expanded adjacent the blue field. C) XSRF-EnR enlarged the expression domain of
XmyoD. D) The enlarged expression of XmyoD could not be repressed by injection of 2 times of
XSRF mRNA. The blue staining marks the injection site (red star). The embryos are viewed
from vegetal pole with anterior facing up.
Table 4. 6 XSRF effects on XmyoD expression
mRNA Injection Normal or almost
Normal
Weaker and/or
more Restricted
Stronger and/or
Expanded
n
XSRF-WT 200pg 14% 86% 28
XSRF-EnR 200pg 11% 2% 87% 53
XSRF-WT 100pg
XSRF-EnR 200pg
100% 16
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overexpression of wild type SRF protein alone should have no effect on XmyoD mRNA
levels. Coinjection of SRF-EnR with wt SRF should rescue XmyoD expression.
Surprisingly, I found that SRF-EnR enlarged the XmyoD expression domain to the
neurula stage (Figure 4.9C). Wild type SRF protein, however, inhibited XmyoD
expression in the injected region and at the time caused expansion of the XmyoD domain
directly adjacent to the injection site (Figure 4.9B). Furthermore, coinjection of mRNA
for wild type SRF and SRF-EnR at a 2:1 molar ratio failed to revert the SRF-EnR
phenotype of a broadened XmyoD domain (Figure 4.9D). SRF protein is maternally
expressed in the Xenopus egg.
In line with the mouse SRF (-/-) phenotype, which indicates a very early function for SRF
in mesoderm formation, we suspected that the above effects on XmyoD expression,
which were achieved by mRNA injection, could be the result of interference with
maternal SRF functions, rather than later functions during mesodermal patterning. In
order to circumvent these problems, I expressed SRF-EnR by transgenesis after the MBT.
Figure 4.10 Transgenic embryos were produced and XmyoD expression was analyzed at stages
NF 12.5 by whole-mount RNA in situ hybridization. A: The embryo without a transgene of
XSRF-EnR showed normal XmyoD expression. B: The expression of XmyoD was repressed in
XSRF-EnR transgenic embryo. All the embryos are viewed from the dorsal side with anterior
facing up.
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Table 4.7. XSRF-EnR repress the expression of XmyoD
Marker Transgenesis Fluorescence Normal/near
normal
Weaker n
- 100% 15XmyoD PCS2+GFP
+
PCS2+XSRF-EnR + 36% 64% 56
I generated double-transgenic embryos with pCS2+GFP and pCS2+XSRF-EnR plasmids.
In this experiment, GFP-expression identifies REMI-embryos, which integrated and
express the transgenes. Independent studies in our and other labs has demonstrated co-
expression of marker genes in double-transgenic embryos to occur at a frequency ≥ 96%
(Otto and Rupp, unpublished result; Hamilton et al., 2001). The embryos were fixed at
stage NF12.5, sorted into two groups: GFP positive (GFP+) and GFP negative (GFP-)
and subjected to RNA in situ hybridization for endogenous XmyoD mRNA. In the non-
transgenic embryos (GFP-), the expression of XmyoD was normal (Figure 4.10A and
Table 4. 7). In contrast, the GFP+ embryos, which express SRF-EnR, showed a much
reduced XmyoD expression (Figure 4.10B and Table 4.7). This indicated that XSRF-EnR
largely down-regulated the expression of XmyoD. The expression pattern of XmyoD in
these embryos (Figure 4.10B) was very interesting. The most anterior and posterior
domains showed more XmyoD mRNA than the region in between. While the reason for
this graded response of XmyoD transcription to constitutively expressed SRF-EnR is
unclear, it clearly shows that SRF-EnR does not interfere with the induction of XmyoD
transcription, but inhibits the maintenance of XmyoD after the induction. This observation
supports our hypothesis that XSRF binds with the SRE box and maintains the expression
of XmyoD, so the dominant-negative XSRF, XSRF-EnR, also binds with the same box
and represses the maintenance of XmyoD expression.
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4.1.8 Analysis of TCF binding site and FAST binding site
Wnts and Nodals are important mesoderm induction factors. In order to test the role of
these factors in XmyoD transcription, mutation constructs were generated that contained
mutations in either the TCF or FAST binding sites in the -1.8/-1.6kb region. TCF is a
transcription factor of Wnt signaling (Molenaar et al., 1996). FAST is a transcription
factor of Nodal signaling (Hill, 2001). A second TCF site (300 bp upstream to the
transcription start site of XmyoD) was also mutated. No significant change in expression
level of the reporter gene was observed in any of these mutation constructs (Table 4. 8).
Table 4. 8 Expression of mutation constructs at stage NF10.5
Construct Correct expression Incorrect
expression
No expression n
mTCF in -1.8/-1.6 61% 7% 32% 122
mFAST in -1.8/-1.6 69% 7% 24% 114
mTCF (–300bp) 65% 8% 28% 65
4.1.9 Non-coding RNA transcripted in 5’ region of XmyoD genomic sequence
Randomly integrated transgenes receive input from the genomic environment of their
integration site, leading to partial ectopic expression. The observed very high frequency
of correct transcriptional regulation without significant ectopic expression of the pMD-
3200/+4829GFP transgene (77%, n=117) is, therefore, quite unusual. In particular, each
of the transgenic embryos represents independent integration events (Kroll and Amaya,
1996). This suggests the presence of some epigenetic regulatory elements, which
uncouple the transgene from influence of the surrounding DNA, such as locus control
region (Engel and Tanimoto, 2000), insulator elements (Bell and Felsenfeld, 1999) or
cellular memory modules (Cavalli and Paro, 1998). In many cases, non-coding transcripts
have been found to originate from the neighborhood of these elements, and these non-
coding RNAs may be involved in the function of these elements (Rank et al., 2002).
Given the exceptional reliability of correct spatiotemporal regulation of the full length
XmyoD transgene, we decided to search for genomic transcripts in the vicinity of the
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XmyoD transcriptional unit by RNA in situ hybridization. For this purpose, I generated a
series of plasmid templates from the upstream region of the XmyoD gene, which were
used to generate both sense and antisense RNA specific in situ hybridization probes. An
overview of these constructs is shown in Figure 4.11.
In the first round of the experiment, I used the sense and anti-sense probes of XLC14,
XLC15, XLC04, and XLC09. Surprisingly, both sense and anti-sense of XLC04 detected
some transcripts (Figure 4. 12, Figure 4. 13). In contrast, none of the other probes
(XLC14, XLC15 and XLC09) detected any transcript. I further narrowed down the
transcript by splitting the XLC04 fragment into three shorter fragments: XLC16, XLC17
and XLC18. In that series of RNA in situ hybridizations, only XLC18 detected the same
expression patterns of transcripts as XLC04 did. This result suggests that the XLC18
fragment in the upstream region of XmyoD produce both sense and anti-sense transcripts,
but the flanking regions do not produce transcript.
Figure 4.11 Schematic representation of dig-labeled probes. The blue bars represent the XmyoD
exon, the red bars represent the DNA fragment to synthesize dig-labeled probes for in situ
hybridization and the arrow indicates the transcription start site. For each fragment I synthesized
sense and anti-sense probes. The regions of the fragments are: XLC04: -3.2/-1.5kb; XLC09: -1.5/-
0.4kb; XLC14: -5.7/-3.9kb; XLC15: -3.9/-3.2kb; XLC17: -2.0/-1.5kb; XLC18: -2.8/-2.0kb;
XLC16: -3.2/-2.8kb.
The expression pattern of the non-coding RNA detected by anti-sense probe is shown in
Figure 4.12. The anti-sense probe detected a maternally expressed RNA in the animal
pole region. After the zygotic expression starts, the signal localizes to the nucleus. The
RNA can be seen in the nucleus of every cell in the embryo at stage NF10. This RNA
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represents the recent onset of zygotic transcription of these units. At stage NF11 the RNA
is dispersed or degraded. At stage NF14 there is no clear expression pattern. At stage
NF18 the anterior part of the embryo shows stronger staining than any other part in the
body. After stage NF 28 strong staining can be seen in the epidermis and in the cells
between the myotomes.
Figure 4.13 shows the expression pattern of the non-coding RNA detected by the sense
probe. Before MBT, the sense probe detected a maternal expressed RNA in the vegetal
cortex. After MBT, the zygotic expression starts and the staining signal localizes in the
nucleus, similar the transcript detected by anti-sense probe. At stage NF10, the RNA can
be seen in the nucleus of all the cells. At stage NF11, the RNA is dispersed or degraded.
At NF14, no clear expression pattern can be seen. At stage NF18, the anterior part of the
embryo shows stronger staining than the other parts of the embryo. At stage NF26, a very
strong staining can be seen in epithelia. After stage NF 28, strong staining can be seen in
the cells between the myotomes and the staining also can be seen in epidermis.
Both sense and anti-sense transcripts have the same expression pattern at stage NF10 and
disappear at stage NF11. This may reflect hybridization of the two transcripts at NF10
and formation of double strand RNA (dsRNA). The dsRNA may be broken into small
pieces by RNAi (RNA interference) machinery (Jenuwein, 2002). The RNA probes used
in these in situ hybridization experiments only recognize single stranded RNA (ssRNA),
but not the dsRNA. So what I detected are the expression patterns of transcripts existing
as ssRNA.
4.1.10 The transcripts are produced by a repetitive sequence
A DNA repetitive sequence in XLC04 and XLC18 was identified through a BLAST
search. It showed high similarity with Xenopus genomic sequence named Xenopus leavis
short interspersed repeat transcripts (Xlsirt) reported by Spohr et al. (1984). They are
93% identical (Figure 4.14) and contain eight copies of a tandemly repeated unit of 79-81
nucleotides.
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Figure 4. 12. The expression pattern of the repeats detected by XLC04 anti-sense probe. The
stages of the embryos are indicated in the top left of the picture. VP=vegetal pole view; L=lateral
view; AP=animal pole view; An=Anterior view; D=dorsal view.
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Figure 4.13 The expression pattern of the repeats detected by XLC04 sense probe. The stages of
the embryos are indicated in the top left of the picture. VP=vegetal pole view; L=lateral view;
AP=animal pole view; An=Anterior view; D=dorsal view.
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The DNA repetitive sequence in the XmyoD locus was given the name MyoD’s Xlsirt
(M-sirt). M-sirt might produce sense and anti-sense transcripts (Figure 4.12, 4.13). The
flanking regions of Xlsirt and M-sirt are unique and do not produce transcript.
Figure 4.14. Sequence alignment of Xlsirt and M-sirt (ClustalW software). Dark shading:
identical nucleotides. The red vertical lines indicate the boundary of the repeated units.
4.2 Analysis of potential regulators of XmyoD expression
4.2.1 XSEB-4
RNA binding proteins play key roles in the regulation of gene expression (reviewed in
Burd and Dreyfuss, 1994). XSEB-4 codes for a putative RNA binding protein containing
a single RNA recognition motif (RRM) (Fetka et. al, 2000) and has been identified as a
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direct target gene of XmyoD protein (Jasper, 1998). XSEB-4 shares 60-65% identity with
the mammalian SEB-4 proteins. XSEB-4 is strongly expressed maternally. Zygotic
transcription is initiated in the early gastrula embryo in paraxial mesoderm that is fated to
give rise to somites. During the course of gastrulation and neurulation, XSEB-4
expression in somitic paraxial mesoderm is centered within the XmyoD expression
domain. As development proceeds, XSEB-4 expression is in addition initiated in the
cardiac primordium and the lens vesicle. In the heart, expression is confined to the
myocardium (Fetka et. al, 2000). Thus, the RRM-containing putative RNA binding
protein XSEB-4 is a good candidate to regulate XmyoD during embryonic development in
Xenopus.
4.2.1.1 The subcellular localization of XSEB-4
To determine the subcellular localization of XSEB-4, I injected mRNA of different
version of myc-tagged XSEB-4 at the 4-cell stage in the animal pole. At stage NF9, the
embryos were fixed in 1X MEMFA to perform immunocytochemistry (ICC) or collected
for western blotting to determine the protein level. ICC and western blotting were
performed with anti-myc antibody.
XmyoD (RR 107 is the plasmid containing XmyoD gene) is used as a control, it mainly
localized in the nucleus in lateral marginal zone (Rupp et al., 1994), and slight cytoplasm
expression also could be observed. This is also true for mLong (long version of mouse
SEB-4), mShort (short version of mouse SEB-4), XSEB-4WT (wild type of Xenopus
SEB-4), and XSEB-4∆C (C terminal truncated version of Xenopus SEB-4). XSEB-4∆N
mainly localized to cytoplasm (Figure 4.15). This suggests the presence of a NLS
(Nuclear Localization Signal) in the N-terminal region. I also observed that XSEB-4∆N
is around 10 times more unstable than XSEB-4WT or XSEB-4∆C (Figure 4. 16), perhaps
the result of its altered cellular localization.
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Figure 4.15 The subcellular localization of XSEB-4.
To determine the subcellular localization of XSEB-4, 150pg mRNA of different version of myc-
tagged SEB-4 were injected in animal pole at 4-cell stage. At NF9, the embryos were fixed in
1X MEMFA, ICC was performed with anti-myc antibody. A: XmyoD mainly localized in the
nucleus in lateral marginal zone, while slight cytoplasm expression also could be observed. This
is also true for mLong (long version of mouse SEB-4) (B), mShort (short version of mouse SEB-
4) (C), XSEB-4WT (wild type of Xenopus SEB-4) (D), and XSEB-4∆C (C terminal truncated
version of Xenopus SEB-4) (F). XSEB-4∆N mainly localized in cytoplasm (E). Abbreviations:
mLong: long version of mouse SEB-4; mShort: short version of mouse SEB-4; XSEB-4WT:
wild type of Xenopus SEB-4; XSEB-4∆C: C terminal truncated version of Xenopus SEB-4;
XSEB-4∆N: N terminal truncated version of Xenopus SEB-4.
Figure 4.16 150 and/or 1500 pg mRNA of different version of myc-tagged XSEB-4 were
injected in animal pole at 4-cell stage. The embryos were collected for western blotting to
determine the protein level at stage NF9.
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Figure 4.17 150 pg different version of XSEB-4 mRNA were injected in the animal pole at 4-
cell stage, and the ACs were explanted at NF 9 and lysed by Trizol (GibcoBRL) at NF 18. The
expression of XmyoD was assayed by RT-PCR. The ACs were separated into 2 groups for every
injection. Only the injection of wild type of XSEB-4 mRNA resulted in the induction of XmyoD.
DC=Delta C; DN=Delta N.
4.2.1.2 XSEB-4 induces XmyoD expression in animal cap assay
I further checked the ability of XSEB-4 to induce XmyoD expression in the animal caps
(ACs). Different version of XSEB-4 mRNA were injected in the animal pole at the 4-cell
stage, and the ACs were explanted at stage 9. ACs were lysed by Trizol (GibcoBRL) at
stage NF 18. The expression of XmyoD was assayed by RT-PCR. There was no XmyoD
expression in control Acs. Wild type XSEB-4 did induce the expression of XmyoD, but
XSEB-4∆N and XSEB-4∆C could not induce XmyoD (Figure 4. 17). This indicated that
XSEB-4 is sufficient to induce the expression in ACs, and both the N- and C- terminal
domains of XSEB-4 are necessary for the activity of XSEB-4 to induce XmyoD.
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4.2.2 YY1
The transcription factor Yin Yang 1 [YY1 (also known as, NF-E1, UCRBP, and CF1)]
is a 65 kDa member of the GLI-krueppel family of zinc finger transcription factors and is
a homolog of the Drosophila polycomb group (PcG) protein pleiohomeotic (Pho). Satijn
et al. (2001) reported that YY1 interacts specifically with the human PcG protein EED,
while PcG proteins form multimeric protein complexes that are involved in the heritable
repression of genes. When the Xenopus homolog of YY1 or YY1-EnR are expressed
ectopically in Xenopus embryos, ectopic neural axes formed, but no mesoderm was
induced (Satijn et al., 2001). We found a potential YY1 binding site near the transcription
start site of XmyoD. It is possible that YY1 functions with polycomb group proteins to
maintain the silence of XmyoD in the region where XmyoD should not be expressed.
Figure 4. 18 XYY1-EnR represses the expression of XmyoD. 100 pg XYY1-EnR mRNA was
injected in LMZ unilaterally at 2-cell stage. XmyoD gene expression was analyzed at stages NF
12 by whole-mount RNA in situ hybridization. The expression of XmyoD was repressed in the
injected side (Red arrow). The embryo is viewed from the vegetal pole with dorsal side facing
up.
In order to determine the function of YY-1 on the expression of XmyoD, 100 pg of
XYY1-EnR mRNA was injected in LMZ unilaterally at the 2-cell stage. XmyoD gene
expression was analyzed at stage NF 12 by whole-mount RNA in situ hybridization. The
expression of XmyoD was repressed in the injected side (93%, n=60) (Figure 4.18).
Therefore, it can be concluded that YY-1 functions to repress the expression of XmyoD.
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4.2.3 Lef-1
The canonical Wnt pathway has been studied extensively during the past decade. It has
been shown that maternal Wnt signaling activity induces the Spemann organizer (for
review see De Robertis et al, 2000). Zygotic Wnt/ß-catenin signaling is essential for the
ventro-posterior development and the activation of XmyoD (Hoppler et al., 1996). TCF-3
is dispensable for the activation of XmyoD (Hamilton et al., 2001). Hamilton et al. (2001)
showed that the maternal and zygotic Wnt signaling could employ different transcription
factors. It is presumed that the zygotic Wnt signaling functions via Lef-1instead of TCF-
3.
Since it has been shown that the protein produced from a transgene is synthesized as
early as stage 10 (Kroll and Amaya, 1996), I generated transgenic embryos that expressed
either dominant active or dominant negative forms of Lef-1 to interfere with the activity
of Lef/Tcf proteins zygotically. I generated pCS2+Lef-1-VP16 and pCS2+GFP double-
transgenic embryos. In this case, GFP expression served as an indicator of successful
transgenesis (Hamilton et al., 2001). Transgenic embryos with fluorescence were sorted
out. The majority of these transgenic embryos failed to undergo epiboly. As a result of
this morphogenetic failure, the ectoderm of these embryos shrank and formed a small cap
upon a mass of vegetal cells (Table 4. 9, Figure 4.19E). Surviving embryos developed
with severe anterior defects and a shortened dorsal axis (Table 4. 9; Figure 4. 19C). When
such embryos were assayed at mid-gastrula for marker gene expression, most of them
showed ectopic expression of ventral and lateral mesodermal markers (XmyoD, Xpo;
Figure 4. 20E and 20F, compare with control embryos in Figure 4. 20B and 20C), which
extended dorsally and occupied the organizer region. However, the expression of the
notochord-specific dorsal mesodermal marker, Xnot was unchanged (Figure 4. 20D,
compare with 20A).
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Figure 4.19 Loss- or gain-of Lef-1 activity results in severe developmental defects
C-F: PCS2+GFP and p-Lef-1-VP16 co-transgenic embryos were analyzed by morphology at
stage 29. Transgenic embryos either fail to undergo epiboly (E) or have a ventro-posteriorized
phenotype (C). D, F: The same embryos as in (C) and (E) are observed under UV light. G-J:
pCS2+GFP and p-Lef-1-EnR co-transgenic embryos were analyzed by morphology at stage 29.
The trunks and tails are totally absent from transgenic embryos, while the heads develop
normally (G, I). H, J, the same embryo as in (G) is observed under UV light. As a control,
transgenic embryos with GFP over-expression alone develop into well-organized embryos (A,
B). All the embryos are lateral view, with anterior to the left.
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In contrast to gain-of Lef-1 activity, Lef-1-EnR transgenic embryos developed severe
posterior defects but normal head structure (Table 4.9, Figure 4.19G). In the extreme
cases, the tails and trunks of transgenic embryos were completely absent (Figure 4.19I).
Loss of Lef-1 activity leads to reduced expression of XmyoD and Xpo (Table 4. 10 and
Figure 4.20H and 20I, compare with 20B and 20C) while Xnot expression is unaffected
(Table 4. 10 and Figure 4.20G, compare with 20A). These results are strictly dependent
on loss- or gain-of Lef-1 activity because expression of GFP alone did not cause this
phenotype (Table 4.10 and Figure 4.20A-C). In a recent study, Roel et al. (2002)
generated similar anteriorized embryos by using a mopholino to deplete XLef-1. From
these results, it is concluded that Lef-1 proteins are not only sufficient but also necessary
for the expression of XmyoD and ventro-posterior development in Xenopus embryos.
Table 4. 9 Lef-1 dependent zygotic Wnt signaling ventro-posteriorizes the embryo
Transgenesis GFP Normal and
almost Normal
Trunk
Defect
No
Head
No
Tail
Failure in
Gastrulation
Other
Phenotype
n
- 100% 9pCS2+GFP
+ 81% 12% 63
- 100% 8Lef-Vp16 and
pCS2+GFP
+ 18% 13% 13% 55% 82
- 100% 21Lef-EnR and
pCS2+GFP
+ 23% 50% 1% 25% 1% 108
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Figure 4. 20 Loss- or gain-of Lef-1 activity results in change of the expression of ventral and
lateral markers.
D-F: PCS2+GFP and p-Lef-1-VP16 co-transgenic embryos were analyzed by molecular marker
expression at stage 11. Analysis of molecular markers show the ectopic expression of ventral
and lateral markers XmyoD (E) and Xpo (F) in the dorsal midline (compared with B, C) and
unchanged the expression of dorsal marker Xnot (D, compared with A). G-I: PCS2+GFP and p-
Lef-1-EnR co-transgenic embryos were analyzed by molecular marker expression at stage 11,
the expression of Xnot is comparable with the control expression (G, A). The reduction of
ventro-lateral gene expression of XmyoD and Xpo is consistent with the reduced ventro-posterior
development (H, I compared with B, C). As a control, transgenic embryos with GFP over-
expression alone show normal expression patterns of indicated molecular makers (A-C). All are
vegetal view, with dorsal up.
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Table 4. 10. Xlef-1 Interferes with ventral and lateral mesoderm patterning
Marker Transgenesis Weaker and/or
 more restricted
Normal or
near normal
Stronger and/or
expanded
n
PCS2+GFP 10% 90% 30
Lef-1-VP16 21% 79% 19
XmyoD
Lef-1-EnR 76% 24% 33
PCS2+GFP 7% 83% 10% 29
Lef-1-VP16 18% 82% 22
Xpo
Lef-1-EnR 46% 54% 35
PCS2+GFP 22% 78% 23
Lef-1-VP16 20% 80% 20
Xnot
Lef-1-EnR 18% 82% 33
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5 Discussion
In Xenopus, the activation of the myogenic determination factor XmyoD in the muscle-
forming region of the embryo occurs in response to mesoderm-inducing factors (MIFs).
Different members of the FGF, TGF-beta, and Wnt protein families have been implicated
in this process (Steinbach et al., 1998), but how MIFs induce the expression of XmyoD is
not known. The expression of XmyoD is thought to have three stages: ubiquitous low-
level transcription at the MBT; full activation at mid-gastrula stage in myogenic
precursors; maintenance after full activation in myogenic precursors. The expression of
XmyoD at these three stages may involve different mechanisms, which are still unknown.
The cis-regulatory elements of the XmyoD gene are the intermediary between the
mesoderm-inducing factors and transcription of the XmyoD gene. In order to understand
the regulatory mechanisms of XmyoD, the cis-regulatory elements of the XmyoD gene
were characterized by a transgenic reporter assay. Several cis-elements were
characterized, including one induction enhancer motif, one silencer motif and one
maintenance enhancer motif. Several potential protein factors, which may regulate the
expression of XmyoD, were also analyzed in this study.
5.1 Methodological considerations
Transgenic reporter analysis by REMI (Restriction Enzyme Mediate Intergration) in
Xenopus provides a good method to search for cis-regulatory elements. Unlike embryos
injected with plasmids, transgenic embryos show the correct spatial and temporal
regulation of the integrated promoter constructs (Lerchner et al., 2000, Polli  and Amaya,
2002, Yang  et al., 2002 and Figure 2.6B). One of the great advantages of this system
over transgenesis in mice or zebrafish is that the transgene is integrated into the male
genome prior to fertilization, therefore the resulting embryos are not chimeric and
breeding of animals is not required. This technique permits large scale transgenesis in
Xenopus. When this method is used to study the regulation of promoters of genes, the
regulatory region of “the gene of interest” is ligated to a reporter gene like GFP, which is
nontoxic, and does not interfere with the development of the embryo. The expression of
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the reporter gene is co-regulated with the endogenous gene during the normal
development of the embryos. The expression of GFP can be analyzed by either GFP
microscopy or in situ hybridization. When the results of transgenic embryos harboring
different presumptive cis-regulatory elements are compared, information can be obtained
about the location and function of these elements.
Expression of the XmyoD gene in mesoderm at mid-gastrula stages may be achieved by
induction of MIFs and XmyoD autocatalysis afterwards (Steinbach et al., 1998). The co-
regulation of reporter gene and endogenous XmyoD also raises a disadvantage: even if the
cis-element responsible for induction is missing from the reporter constructs, the correct
expression of the reporter gene can be achieved as long as the cis-element responsible for
XmyoD’s autocatalytic loop is present. Direct autocatalysis would involve either E-boxes
(the binding motif of bHLH protein like MyoD, Perry and Rudnicki, 2000) or MEF-2
binding sites, since MyoD can transactivate transcription through protein-protein
interactions with MEF-2 family members (Molkentin et al., 1995). However, the MIE
element contains neither of these binding sites. Thus, the LS-5 motif represent an
essential regulatory element for the induction of XmyoD transcription, independent from
MyoD’s autocatalytic circuitry.
To begin the search for cis-regulatory elements, a series of truncation and deletion
constructs were assayed by transgenic reporter analysis. Second, a linker-scanning
strategy was used to define discrete motifs of the enhancer or silencer. It should be noted
that all the linker-scanning mutations were tested within the context of –3200/+4829bp
fragment. This genomic region is able to recapitulate all major aspects of endogenous
XmyoD regulation. It should also be noted that cis-regulatory elements may have
redundant functions (see e.g. Chen et al., 2002). Therefore, some elements may be missed
if their functions are compensated by other cis-elements. Consequently, all elements
identified by REMI in this study have dominant activaties.
The REMI transgenesis technique also provides a tool for researchers to target gene
expression to specific cell types in Xenopus. Compared with REMI, mRNA and episomal
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DNA plasmid injections lack temporal and spatial specificity. For example, DNA
plasmids which use tissue-specific promoters to drive expression are poorly regulated
when injected into Xenopus embryos and lead to mosaic expression. Thus, if one is
interested in targeting or labeling a particular embryonic region, tissue or cell type,
neither of these techniques provides the desired level of specificity. With the REMI
technique, we can achieve this. For example, in this study, it has been shown that the
–3200/+4829bp region of the XmyoD gene is sufficient to drive expression of the reporter
gene in a manner very similar to endogenous XmyoD. The XmyoD regulatory region,
which has been characterized by REMI in this work, provides a powerful tool for targeted
expression of regulater genes or interference variants to test the myogenic regulatory
network in situ at the time of muscle determination.
5.2 Cis-regulatory elements that regulate the expression of XmyoD
5.2.1 Expression of XmyoD is regulated through activation and repression
It has been demonstrated that the proximal promoter sequences of XmyoD (up to –0.7kb)
leads to activation of reporter gene expression in ectoderm, but not in mesoderm. This
indicated that the correct expression of XmyoD requires repression in ectoderm and
activation in mesoderm. It has been further shown in this work that multiple enhancer
elements in the XmyoD regulatory region contribute to full activation of XmyoD. The
region spanning position -840 to -704 of the XmyoD locus appears to have significant
importance on the regulation of XmyoD. We call this region MIE (MyoD induction
enhancer). Specifically, the MIE region contains a repressing (LS-9) and a activating
(LS-5) elements (Figure 4.5). Taken together, the correct expression of XmyoD is
regulated by a combination of activation and repression.
For the Xbra and Xmyf-5 gene, it was also found that the regulations are dependent on a
complex interplay of repression and activation (Lerchner et al., 2000, Polli and Amaya,
2002, Yang et al., 2002). These suggested that the restriction of XmyoD, Xbra, Xmyf-5
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expression to the mesoderm of the early Xenopus embryo is achieved by general
activation followed by repression in ectoderm.
LS-9 motif has been shown to be a silencer. However, the LS-9 motif does not account
for all the repression. Because if LS-9 is the only silencer, we should expect that the
expression of LS-9 mutation construct should be very high in ectoderm but not in
mesoderm, like that of the short promoter. In fact, the LS-9 mutation construct only
showed precocious expression in mesoderm at NF10, expanded expression of reporter
gene at NF10.5 and ectopic expression in the posterior wall (PW) of the neuroenteric
canal at tail bud stage (Figure 4.4 C-F). Therefore, additional silencers should be further
characterized, they may co-operate with LS-9 motif to silence the ectopic expression in
ectoderm.
5.2.2 LS-5 motif
Analysis of the LS-5 mutation construct showed a loss of most of the expression of the
reporter gene at NF10.5 and at tail bud stages (Figure 4.4 A, B and Table 4.2). Therefore,
the LS-5 motif mediates an essential activating function of XmyoD induction.
To ascertain, whether any potential protein binding site is found within the LS-5 region,
we searched for putative binding sites and discovered that a consensus CdxA binding site
lies within the LS-5 motif. CdxA is a member of the caudal protein family. In Xenopus,
members of the caudal protein family have previously been shown to be downstream of
eFGF signaling and act as transcriptional activators for the posterior genes (Isaacs et al.,
1998). However, the gain-of-function and loss-of-function analysis of the caudal related
gene Xcad-3 did not give us expected result. This means that the LS-5 motif should be
bound by other transcription activator.
A recent paper characterized eFGF as an inducer of XmyoD expression (Fisher, et al.,
2002). This prompted me to ask which region in the XmyoD genomic sequence is
responsible for the induction by eFGF.
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It is shown in this study that eFGF is able to induce XmyoD expression by mRNA
injection in the animal pole. It is also found that both the -840/-704 bp region and the LS-
5 motif are essential for the induction. The -1770/-1586bp region also contributes to the
induction (Figure 4.5 and Table 4.3). So it is concluded that both the -840/-704 region
and the LS-5 motif are essential for the induction of XmyoD by eFGF signaling; LS-5
motif accounted for most of the reduction caused by deletion of -840/-704 region. Taken
together, this indicated the LS-5 motif is the most important enhancer for the induction of
XmyoD by eFGF.
Although it is shown that LS-5 motif is essential for the induction of XmyoD by eFGF, it
is difficult to distinguish whether the LS-5 motif is bound by a factor which is induced by
eFGF signaling or if the LS-5 motif is bound by an essential factor, which functions in
parallel or downstream, but independent from eFGF signaling. In order to test these two
possibilities, we should construct a plasmid in which a TK minimal promoter is driven by
the LS-5 motif. We can inject eFGF mRNA in the transgenic embryos that contain this
construct to test whether or not the LS-5 motif responds to eFGF signaling.
While it is clear that LS-5 is necessary to drive the expression of the reporter gene, it
remains unclear whether or not the LS-5 motif is sufficient to achieve a correct
expression pattern of the reporter construct. In order to test this possibility, it may be
necessary to construct the LS-5 motif with a minimal promoter to drive a reporter gene,
and analyze the expression of the reporter gene by REMI. If this construct shows an
XmyoD-like expression pattern, then we can conclude that the LS-5 motif is also
sufficient for the expression of XmyoD gene.
5.2.3 LS-9 motif
5.2.3.1 The LS-9 motif functions as a silencer
The LS-9 mutation construct showed precocious expression of the reporter gene before
stage NF10 and stronger, expanded expression of the reporter gene at stage NF10.5. At
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tailbud stages, expression was also observed in the posterior wall (PW) of the
neuroenteric canal (Figure 4.4 C-F), which does not produce muscle. It is therefore
concluded that the LS-9 region contains an element that mediates transcription
repression.
Two possible mechanisms exist by which the LS-9 motif silences the ectopic expression
of XmyoD. First, the LS-9 motif may be bound by a protein factor, which functions as a
transcriptional repressor to repress the ectopic expression of XmyoD. Alternatively, the
LS-9 motif may not be bound by transcription factor. Instead, the CpG dinucleotide,
located in the LS-9 motif may be methylated, which may serve as an epigenetic mark for
the repression. Methylation occurring at CpG-dinucleotides in LS-9 may result in the
formation of transcriptionally silent heterochromatin. The enhancer motif, LS-5, that is
located 45 bp upstream of LS-9 may be affected by the neighboring heterchromatin and
thus rendered inaccessible by transcriptional activators. In support of this argument, the
CpG-dinucleotide in the LS-9 motif is the most upstream of several CpG motif in the
third CpG island in XmyoD gene locus, the LS-10 motif contains the second CG
dinucleotide of this CpG island. However, the mutation of the LS-10 motif did not result
in any change of the reporter gene expression compared with that of the wild type
construct (Table 4.2). These observations may reflect that the first CpG dinucleotide in a
CpG island is more important for the initiation, relay, or propagation of the methylation.
5.2.3.2 Temporal regulation of the XmyoD gene
XmyoD can be induced in animal caps (ACs) by several mesoderm-inducing factors
(MIFs) like Activin or Wnt8/bFGF (Steinbach et al, 1998). It has been shown that MyoD
induction depends on the developmental age of the induced cells, rather than on the type
or time point of inducer application (Steinbach et al, 1998 and Figure 2.6B, h, i). This
implies that the expression of XmyoD is tightly controlled by a timing device.
In wild type embryos, XmyoD expression starts at stage NF10.5. The
pMD–3200/+4829GFP reporter constructs also recapitulate the timing of XmyoD
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expression. However, mutation of the LS-9 motif in the reporter construct resulted in
precocious expression of the reporter gene before NF10 (Figure 4.4 C). This indicated
that the LS-9 motif may contain the timing device, or a component of it, which controls
the expression of XmyoD. The mechanism by which LS-9 serves as a timing device is
currently under investigation.
5.2.3.3 Xvents may regulate XmyoD transcription via LS-9
Xvent-1 and Xvent-2 are homeobox genes. They are expressed in the ventral and lateral
marginal zones of Xenopus embryos and are excluded from most of the dorsal regions at
mid-gastrula stages. At tail bud stages, Xvents are expressed in the posterior wall (PW) of
the neuroenteric canal. They have been shown to be an immediate response gene of
BMP-4 signaling and function in BMP signaling as transcriptional repressors
(Onichtchouk et al, 1998). Xvent-2 can also act as an activator, e.g., BMP-autoactivation
(Schuler-Metz et al., 2000). The expression of Xvents overlaps with the ventral domains
of XmyoD expression pattern at mid-gastrula stages, at the same time the ventral domains
of the XmyoD expression pattern are weaker in expression intensity than the dorsal
domains. The expression of XmyoD is excluded from the posterior wall of the
neuroenteric canal where Xvents are expressed. These data imply that Xvents may be
negative regulators of XmyoD expression.
When the LS-9 motif is mutated, the reporter gene showed expanded expression at stage
NF10.5, the expanded region included the ventral marginal zone, a region where Xvents
are expressed. The ectopic expression of the LS-9 mutant construct also showed an
overlap with the expression of Xvent-1 and Xvent-2 in the PW of the neuroenteric canal
at tailbud stages (Gawantka et al., 1998). Therefore, XmyoD may be regulated by BMP
signaling through Xvent-1 and Xvent-2 via the LS-9 motif. However, there is no
homeobox found in LS-9 motif. This implies that the Xvents may regulate XmyoD
indirectly or that Xvents bind a non-canonical DNA motif.
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5.2.4 Maintenance enhancer
It has been found that maintenance of XmyoD expression plays an important role in
Xenopus myogenesis after induction of XmyoD expression (Kato and Gurdon, 1993).
Standley et al. (2001) reported that a secreted factor, eFGF, is sufficient for the
maintenance of XmyoD expression, but the mechanism has not yet been elucidated.
It has been shown in this study that Xenopus serum response factor (XSRF) is likely to be
the transcription factor that binds with an SRE box in the 5’ genomic sequence of XmyoD
and functions to maintain the expression of XmyoD. When the SRE box was mutated in a
way to inhibit SRF binding, about 80% of embryos containing the mutation expressed the
reporter gene normally at stage NF10.5, however, only about 50% of embryos showed
some, usually much weaker, expression at tailbud stages. This indicated that around 30%
of embryos lost maintenance of the reporter gene expression. It has also shown that a
dominant negative version of XSRF, XSRF-EnR, largely down-regulated the expression
of XmyoD when it is expressed after MBT. Therefore, these data indicate that XSRF
binds with the SRE box and maintains the expression of XmyoD during development.
Experiments using an electrophoretic mobility shift assays (EMSA) confirmed that XSRF
can bind the SRE box in vitro (Oliver Nentwich, unpublished data), and a CHIP
(Chromatin Imunoprecipitation) assay confirmed that XSRF binds with XmyoD 5’
genomic sequence in vivo (Oliver Nentwich and Katrin Mansperger, unpublished data). It
has also been shown that XmyoD up-regulates the expression of XSRF (Armstrong and
Rupp, unpublished data). Taken together, these data suggest that XmyoD first up-
regulates the expression of XSRF and subsequently XSRF maintain the expression of
XmyoD.
Since both a secreted factor, eFGF, and a transcription factor, XSRF, function to maintain
the expression of XmyoD, it would be interesting to investigate if XSRF functions
downstream of eFGF pathway in the maintenance of XmyoD expression.
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5.3 The expression pattern of M-sirt is correlated with the inactive state of XmyoD
gene
Transcripts of DNA repetitive sequence, which are localized in the -2.8/-2.0kb region of
the XmyoD genomic sequence, were detected by in situ hybridization. We named this
DNA repetitive sequence as M-sirt (MyoD’s Xlsirt). The M-sirt region contains eight
copies of a tandemly repeated unit of 79-81 nucleotides and shows 93% sequence identity
with Xlsirt (Spohr et al., 1984) (Figure 4.14). M-sirt produces both sense and antisense
transcripts and the expression pattern of M-sirt is correlated with the inactive state of the
XmyoD gene (Figure 2.6B, a-c): the transcripts exist in the nucleus in all cells before the
induction of XmyoD at stage NF 10, but at stage NF10.5, when the expression of XmyoD
is upregulated in the mesoderm, the non-coding transcripts of M-sirt are dispersed or
degraded (Figure 4.12, 4.13). Later on, the transcripts of M-sirt never overlap with the
XmyoD expression domains. After the tailbud stage, M-sirt is expressed in the epidermis
and between the somite myotome, while XmyoD is expressed in somite myotome.
Therefore, there is a clear correlation between the transcripts of M-sirt and the inactive
state of XmyoD both spatially and temporally.
Since M-sirt shows 93% sequence identity with Xlsirt, it raises the question of how
specific RNA in situ hybridization is and whether the RNA-signals indeed originate from
the XmyoD locus. Polli and Amaya (2002) reported that in situ hybridization can clearly
distinguish the Xenopus leavis myf5 mRNA from Xenopus tropicalis myf5 mRNA
although they possess 90% sequence identity in the probe region.
To further verify the specificity of the M-sirt in situ hybridization probe, a second in situ
hybridization could be performed using a second, closely related Xlsirt sequence. If non-
identical in situ hybridization staining patterns would be obtained, then the specificity of
the probe would be further supported. RT-PCR experiment with M-sirt specific primers
also should be done to prove that M-sirt is actively transcribed.
5.4 Potential protein factors that regulate the expression of XmyoD
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The expression of a gene is regulated at several levels. Beside cis-regulatory elements,
protein factors also play important roles. In this study, several potential regulatory factors
of XmyoD were analyzed.
5.4.1 Putative RNA binding protein XSEB-4 is able to induce XmyoD expression in
an animal cap assay
RNA binding proteins play diverse roles in the regulation of RNA metabolism in
vertebrates and invertebrates (Burd and Dreyfuss, 1994). XSEB-4, a direct transcriptional
target of XmyoD protein (Jasper, 1998), has a putative RNA recognition motif (RRM). It
is shown in this study that XSEB-4 is mainly localized in nuclei and able to induce the
expression of XmyoD in an animal cap assay. However, which RNA is bound by XSEB4
is unknown. The mechanism by which XSEB4 regulate XmyoD expression is under
analysis.
5.4.2 XYY1
Yin Yang 1 (YY1) is a multifunctional transcription factor that acts as an activator,
repressor, or initiator of transcription of numerous genes (Ficzycz et al., 2001). One
potential YY1 binding site is found in XmyoD’s promoter region. Satijn et al. (2001)
showed that XYY1 functions as a repressor to induce ectopic neural tissue. It is shown in
this study that XYY1-EnR is able to inhibit the expression of XmyoD. However, Ficzycz
et al. (2001) reported that YY1 does not appear in the nuclei of cleavage stage embryos,
nor in gastrula stage embryos several hours past the MBT, nor in neurula stage embryos.
This observation ruled out the possibility that XYY1 functions as transcription factor to
regulate the expression of XmyoD. It also implies that XYY1 regulates XmyoD
expression indirectly. Further analysis should be done to characterize the mechanism that
how XYY1 regulates the expression of XmyoD.
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5.4.3 Lef-1 is necessary and sufficient for the expression of XmyoD
Zygotic Wnt signaling has been shown to be involved in dorsoventral mesodermal
patterning in Xenopus embryos, but how it regulates XmyoD expression in the lateral
mesodermal domains is not clear. Overexpression of XWnt8 during gastrula stages leads
to ectopic XmyoD activation across the dorsal midline, where its expression is normally
excluded (Christian & Moon 1993). Furthermore, dominant-negative forms of XWnt8
inhibit XmyoD expression in the early mesoderm (Hoppler et al. 1996), whereas
overexpressed ß-catenin increases XmyoD expression, thus establishing ß-catenin as the
transcription factor effector for XWnt8-mediated XmyoD activation. Interestingly, TCF-3
is not necessary for the activation of XmyoD (Hamilton et al. 2001). So ß-catenin must
co-operate with other transcription factors to activate XmyoD. This study showed that
Lef-1 is both necessary and sufficient to drive the expression of XmyoD (Figure 4.20),
which provides strong evidence that Lef-1 is a transcription factor of zygotic Wnt
signaling that activates the expression of XmyoD.
5.5 Conservation of MyoD regulation
How conserved is the MyoD regulation among the different species? In human and
mouse, a 258 bp element located 20 kb upstream of the MyoD gene had been isolated.
This so-called core enhancer can drive the expression of a LacZ reporter in the myotome
(Goldhamer et al., 1992; Goldhamer et al., 1995). By linker scanning mutations, one
element has been isolated that is dependent on Myf-5 activation (Kucharczuk et al.,
1999). No additional activator of the core enhancer has been found so far, although the
element can weakly activate the LacZ reporter in a Myf-5/MyoD double knock-out
background (Kablar et al., 1999). The function of the core enhancer is independent of the
promoter because it functions with a heterologous TK-promoter (Goldhamer et al., 1992;
Goldhamer et al., 1995). An additional regulatory region named DRR was found 5 kb
upstream of the mouse MyoD gene (Asakura et al., 1995). The DRR also activates the
LacZ reporter in the myotomes but is not active in the Myf-5/MyoD double knock out
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background, indicating that the element is necessary for the maintenance of MyoD
expression (Asakura et al., 1995; Kablar et al., 1999).
In summary the data from the other species show that MyoD expression is regulated by
activation rather than inhibition and that only a few (possibly two) elements are necessary
for the correct regulation of MyoD. This is in contrast to the results of this study because
many different regulatory regions have been isolated which have both repression and
activation functions. Moreover, there is no homology detected between the mouse core
enhancer and the sequences of the frog myoD locus. In conclusion, the regulation of
MyoD expression differs among different species. One likely reason for these apparent
differences is that it is a result of adaptation to the developmental environment. The
placental development of mammals allows for a comparatively slow growth, while the
extracorporal development of the frog requires much faster growth. This rapid
accumulation of muscle could be induced by the early activity of XmyoD, which helps to
build up fast growing muscle.
5.6 A model of the epigenetic regulation of XmyoD
The transcripts of M-sirt were detected by in situ hybridization, and the expression
pattern of M-sirt is correlated with the inactive state of XmyoD gene (Figure 4.12, 4.13
and Figure 2.6B, a-c) both spatially and temporally. This raises the question: what are the
functions of M-sirt and its non-coding transcripts?
Several recent papers have provided insight into this issue by demonstrating the presence
of short RNA transcripts that are complementary to repeats in centromeres and elsewhere
in the genome (reviewed by Jenuwein, 2002). Jenuwein (2002) has proposed a model
based on these observations, which stated that DNA repeats may be nuclear foci for the
generation and accumulation of short heterochromatic RNAs (shRNAs). These RNAs are
important for epigenetic processes associated with initiation and formation of
heterochromatin (Figure 5.1).
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Figure 5.1 Model for heterochromatin formation by shRNA. (A) Shown is a hypothetical genomic region
(black) containing DNA repeats (purple) and a gene or transcription unit (green). Promoter-driven mRNA
is indicated by the wavy line (dark blue), and spurious intergenic transcription is represented by the blue
dashed lines. (B) Simplified model highlighting the hierarchy of processes that induce epigenetic
transitions triggered by shRNAs originating from DNA repeats. (DNMT, DNA methyltransferase.)
(Adapted from Jenuwein, 2002)
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According to this model, M-sirt and its non-coding transcripts may function as a signal to
start the methylation of both histones and DNA to form heterochromatin. Interestingly,
four CpG islands are found near the important regulatory elements of XmyoD (Figure
5.2). These four CpG islands are potential targets of DNA methylation. Among these four
CpG islands, three are between the repeats and the transcription start site of XmyoD and
one is downstream to the transcription start site of XmyoD. The SRE box (maintenance
enhancer motif) is shortly upstream of the most distal CpG island. The LS-9 motif
(Silencer) contains the first CpG dinucleotide of the third CpG island. The LS-5 motif,
which is the main enhancer, is immediately upstream of the third CpG island. The LS-9
motif may contain binding sites for a transcription repressor or be important for its CpG
motif. The observation implies that the CpG dinucleotide may be important for the
correct expression of XmyoD.
When we connect the observations regarding transcripts of M-sirt, CpG islands and the
inactive state of XmyoD, a picture begins to emerge (as shown in Figure 5.2): the
transcripts of the repeats function as a signal to start the methylation of both histones and
DNA, and control the accessibility of the enhancers of XmyoD, then regulate the timing
and maintenance of XmyoD expression.
The M-sirt transcripts may hybridize to each other and form double stranded RNA and
function as a signal to start the methylation of CpG islands and heterochromatin
formation. The methylation of XmyoD locus may finish by stage NF10.5, leaving the
enhancers (LS-5) unaccessible. This corresponds to the point in time when cells lose the
competence to form muscle (Steinbach, et al., 1997).
After XmyoD is up-regulated at stage NF10.5 in mesoderm, XmyoD up-regulates XSRF
(Armstrong and Rupp, unpublished data). XSRF somehow can prevent the process of
methylation to maintain the accessibility of the LS-5 motif and further maintain the
expression of XmyoD at later stages.
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Figure 5.2 The model of the epigenetic regulation of XmyoD. The M-sirt (pink box) produces
transcripts and function as a signal to start the methylation of the four CpG islands (red boxes). The
DNA methylation and heterochromatin formation inhibit the accessibility to MIE (green box) and
further inhibit the transcription of XmyoD. SRF may bind with the SRE (yellow box) to block the
process of methylation.
5.7 Conclusion and outlook
In this study, the transcriptional regulation of XmyoD in Xenopus was analyzed. Three
cis-regulatory motifs were defined: an induction enhancer (the LS-5 motif), a silencer
(the LS-9 motif) and a maintenance enhancer (the SRE box). M-sirt, a repetitive DNA
sequences, was discovered in -2.8/-2.0kb region in the XmyoD genomic sequence. M-sirt
is likely to produce sense and anti-sense transcripts. These may provide an important
epigenetic mark to regulate the expression of XmyoD. Several protein factors have also
been shown to regulate the expression of XmyoD including XSRF, Xcad-3, XSEB-4,
XYY-1 and Lef-1.
This study provided important information for the understanding of XmyoD gene
expression, muscle development and mesoderm patterning. It will be interesting to
determine the protein factors that bind with the LS-5 and LS-9 motifs. The methods we
can use include yeast one-hybrid screening (Sieweke, 2000) or screening phage
expression libraries with these two DNA motifs (Zhang et al., 2002). In order to confirm
if the CpG dinucleotide in the LS-9 motif is important, we may mutate the CG into CC or
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GG, and check the expression of reporter gene by REMI. We also can produce more CpG
dinucleotides in the LS-9 motif or other regions, like the LS-6 motif, and assay for the
effects on expression.
It would also be interesting to test the model of the epigenetic regulation of XmyoD
(shown in Figure 5.2). In order to test this model, we could analyze whether there is
correlation between demethylation of the XmyoD locus and XmyoD gene expression.
Experiments could also be done to test if the overexpression or knockdown of M-sirt
transcripts affects the expression of XmyoD. The best method to address the function of
the repeats in XmyoD locus is to make a targeted deletion of the repeats from the XmyoD
locus by homologous recombination (Chen et al., 2002). Although this method has not
been established in Xenopus, it has been worked out in numerous other species. When we
have a frog line that harbors a targeted deletion of the M-sirt in XmyoD gene locus, we
can easily analyze the phenotype of the frogs and the expression of XmyoD gene to get
information of the function of M-sirt. If this model is proven true, we will gain very
valuable information to understand the regulation of the XmyoD gene expression and
mesoderm patterning.
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